JACC Podcast

JACC - SUMMIT 2024: A Video Interview with Harlan Krumholz and Milton Packer| JACC | AHA 2024 Nov 20, 2024

Join Dr. Harlan Krumholz and Dr. Milton Packer as they discuss the groundbreaking SUMMIT trial, a study poised to redefine treatment for heart failure with preserved ejection fraction (HFpEF) linked to obesity. Dive into the trial's unique methodology, compelling results, and transformative implications for patient care.

JACC - Recap of AHA From Harlan Krumholz, Editor-in-Chief Nov 20, 2024

Harlan Krumholz, editor-in-chief of JACC, provides a wrap-up of the JACC papers at the AHA Scientific Sessions in Chicago in 2024. JACC's Obesity Revolution page features various trials to provide perspectives on obesity, including SUMMIT, LookAHEAD, and SELECT. Other studies featured include the DANGER trial; REALIZE-K; AMPLATZER; HELIOS-B; a study on sedentary behaviors from the UK Biobank; systolic pressure and blood pressure in patients with HFpEF; rural and urban differences in cardiovascular mortality from 2010-2022; and the association of hospital cardiologist integration with patient outcomes

JACC - Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure Nov 20, 2024

JACC Associate Editor Michelle M. Kittleson, MD, PhD, FACC, interviews author Mikhail Kosiborod, MD, FACC about his REALIZE-K study published in JACC and presented at AHA. In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalemia and down-titration/discontinuation of spironolactone. More participants had HF events with SZC than placebo; this difference was limited to those with very high NTproBNP levels.

JACC - Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity Nov 20, 2024

JACC Associate Editor Marc P. Bonaca, MD, FACC, speaks with author Subodh Verma, MD, PhD, and A. Michael A. Lincoff, MD, FACC, about this brief report published in JACC and presented at AHA. Following CABG surgery there remains a markedly high risk of persistent ischemic events, heart failure, and mortality. Semaglutide consistently reduced all cardiovascular outcomes in this population.

JACC - Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Nov 20, 2024

JACC Associate Editor Neha J. Pagidipati, MD, FACC, speaks with author Christopher M. Kramer, MD, FACC about this substudy of the SUMMIT trial published in JACC and presented at AHA, demonstrating that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial.

JACC - Outpatient Worsening Heart Failure in Patients with ATTR CM in the HELIOS-B Trial | JACC | AHA 2024 Nov 20, 2024

JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, talks with authors Scott Solomon, MD, FACC and. Marianna Fontana, MD, about their study published in JACC and presented at AHA. Outpatient worsening heart failure (HF) (oral diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM. In this pre-specified analysis of a contemporary ATTR-CM population, patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events and all-cause mortality, as well as greater deterioration in assessments of functional capacity, health status, and quality of life. Vutrisiran significantly reduced the risk of outpatient worsening HF and the composite of outpatient worsening HF, all-cause mortality, and recurrent CV events compared with placebo.

JACC - Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial Nov 20, 2024

JACC Deputy Editor Erica S. Spatz, MD, FACC, joins author Rishi Wadhera, MD, to discuss his paper on rural and urban differences in cardiovascular mortality in the United States, and the impact of the COVID-19 pandemic.

JACC - Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study Nov 20, 2024

JACC Associate Editor Muthiah Vaduganathan, MD speaks with author Ambarish Pandey, MD about the LookAHEAD trial published in JACC and presented at AHA. Among adults with T2D and overweight/obesity in the Look Action for Health in Diabetes (AHEAD) trial, an intensive lifestyle intervention targeting weight loss led to sustained reductions in hs-cTnT at 1- and 4-year follow-up, and a rise in NT-proBNP at 1 year that attenuated at 4 years. After accounting for baseline biomarker levels and baseline and changes in risk factors, longitudinal increase in NT-proBNP was associated with higher risk of ASCVD and incident HF. In contrast, increase in hs-cTnT was significantly associated with ASCVD but not incident HF.

JACC - DanGer Shock trial: The impact of age | JACC | AHA 2024 Nov 20, 2024

JACC: Associate Editor Celina Yong, MD, interviews author Jacob Eifer Møller, PhD about his DANGER SHOCK paper presented at AHA and published in JACC. The DanGer Shock trial demonstrated reduced mortality in patients with STEMI-related cardiogenic shock treated with a microaxial flow pump (mAFP). This secondary analysis assessed whether age affected survival benefits. Mortality increased incrementally with age, and age was independently associated with outcome. Spline analysis suggested that the risk of mortality was higher in the standard-care group for patients below 77 years, whereas patients aged 77 or older had a higher predicted risk in the mAFP group. Thus, elderly patients may not attain the same benefit from routine treatment with a mAFP as younger patients.

JACC - Oxidized Phospholipids and Calcific Aortic Valvular Disease Nov 20, 2024

JACC Associate Editor Marc P. Bonaca, MD, FACC, has a discussion with author Sotirios Tsimikas, MD, FACC about this study on phospholipids presented at AHA and published in JACC. In MESA, both OxPL-apoB and Lp(a) were independently associated with prevalent AVC with a significant interaction between the two (p less than 0.01). OxPL-apoB and Lp(a) were associated with incident AVC at 9.5 years when evaluated independently (interaction p less than 0.01). The OxPL-apoB*Lp(a) interaction demonstrated higher odds of prevalent and incident AVC for OxPL-apoB with increasing Lp(a) levels. In the meta-analysis, both OxPL-apoB and Lp(a) were independently associated with faster increase in Vmax, but when evaluated together, only OxPL-apoB remained significant. OxPL-apoB is an independent predictor of the presence, incidence and progression of AVC and established AS and represents a novel therapeutic target for CAVD.

JACC - Accelerometer-Measured Sedentary Behavior & Risk of Future Cardiovascular Disease | JACC | AHA 2024 Nov 20, 2024

JACC Associate Editor Xiaoxi Yao, MPH, MS, PhD, FACC, interviews author Shaan Khurshid, MD and Ezimamaka Ajufo, MD, about their study on sedentary behavior presented at AHA and published in JACC. Beyond serving as a marker for insufficient physical activity, sedentary behavior may directly affect risk of future cardiovascular (CV) disease. In 89,530 UK biobank participants, greater accelerometer-measured sedentary time was associated with higher incidence of adverse CV events. Associations with sedentary time were particularly robust for HF and CV mortality, where risk inflected at approximately 10.6 hours/day and remained apparent even among individuals meeting guideline-recommended levels of moderate-to-vigorous physical activity. Future guidelines focused on sedentary behavior should emphasize the importance of avoiding excess sedentary behavior, even among individuals who are active.

JACC - P2Y12 Inhibitor Pretreatment in Non-ST Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry Nov 20, 2024

JACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among those undergoing CABG, underscoring the importance of maintaining efforts to integrate evidence into clinical practice.

JACC - Hospital-Cardiologist Integration and Outcomes | JACC | AHA 2024 Nov 20, 2024

JACC Associate Editor Jason H. Wasfy, MD, MPhil, FACC interviews author Vinay Kini, MD, FACC about this hospital integration study published in JACC and presented at AHA. Cardiologist employment by hospitals is increasing, but the impact on care quality is not well understood. The study identified cardiologists who cared for acute myocardial infarction or heart failure patients between 2008-2019. Outcomes were compared for patients treated by cardiologists who switched to hospital employment versus cardiologists who remained independent. The proportion of hospital-employed cardiologists increased from 26% in 2008 to 63% in 2019. The study found no differences in clinical outcomes (e.g., 30-day mortality) or most quality-of-care metrics between patients treated by hospital-employed versus independent cardiologists. The results do not support purported benefits of hospital employment on care quality.

JACC - Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022 Nov 20, 2024

JACC Deputy Editor Erica S. Spatz, MD, FACC, joins author Rishi Wadhera, MD, to discuss his paper on rural and urban differences in cardiovascular mortality in the United States, and the impact of the COVID-19 pandemic.

JACC - November 26, 2024 Issue Summary Nov 18, 2024

In the November 26, 2024 issue of JACC, Dr. Valentin Fuster highlights four pivotal studies in cardiovascular research. The first explores the independent roles of social determinants of health and polygenic risk scores in coronary heart disease, while the second assesses the impact of recurrent rejection on pediatric heart transplant outcomes. The third paper examines the effects of CSL 112 infusions on reducing ischemic events post-myocardial infarction, and the fourth investigates the interplay between pulmonary hypertension and heart failure with preserved ejection fraction. Each study advances our understanding of cardiovascular risk, treatment, and outcomes.

Associations of Self-reported Race, Polygenic Risk, and Social Determinants of Health with Coronary Heart Disease Nov 18, 2024

In this episode, Dr. Valentin Fuster discusses a groundbreaking study examining how both social determinants of health and polygenic risk scores independently contribute to the risk of coronary heart disease (CHD). The research highlights how factors like income, education, and food insecurity are linked to higher CHD risk, particularly among Black and Hispanic populations, while emphasizing the need to integrate both genetic and environmental factors for more accurate disease prevention models.

Prevalence and Impact of Recurrent Rejection on Pediatric Heart Transplant Recipients: A PHTS Multi-Institutional Analysis Nov 18, 2024

In this episode, a study on pediatric heart transplant recipients highlights the decreasing prevalence of recurrent rejection, yet finds that children who experience multiple rejection episodes face a significantly higher risk of graft loss. Notably, racial disparities were observed, with Black children showing poorer outcomes, suggesting the need for standardized care protocols and a focus on eliminating these inequities in future heart transplant practices.

ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction Nov 18, 2024

In this episode, Dr. Valentin Fuster reviews an exploratory analysis from the 80s2 trial, which examined CSL 112’s impact on ischemic events after acute myocardial infarction. While CSL 112 didn’t significantly reduce cardiovascular death or stroke in the short term, the study found promising long-term benefits, suggesting that enhancing cholesterol efflux could be a valuable approach for reducing recurrent ischemic events in high-risk patients.

Clinical implications of Pre-test probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension Nov 18, 2024

In this episode, Dr. Valentin Fuster reviews a recent study exploring the clinical overlap between heart failure with preserved ejection fraction (HFpEF) and Group 1 pulmonary hypertension. The study identifies a subset of patients with pulmonary hypertension who have a higher risk of heart failure and worse outcomes, emphasizing the need for further investigation into whether pulmonary hypertension therapies could improve prognosis in these patients.

Consequences of Discontinuation of Long-Term Treatment in Patients With Heart Failure and Reduced Ejection Fraction Nov 18, 2024

In this episode, Dr. Valentin Fuster reviews a study on the impact of long-term drug treatment discontinuation in heart failure patients with reduced ejection fraction. He breaks down four pathways of drug withdrawal—ranging from immediate clinical worsening to long-term deterioration—emphasizing the importance of avoiding unnecessary interruptions in treatment to prevent significant health risks.

JACC Journals at AHA | JACC | AHA 2024 Nov 13, 2024

Join Harlan Krumholz, editor-in-chief of JACC, as he highlights groundbreaking cardiovascular science presented at this year's American Heart Association Scientific Sessions. From obesity-related heart failure to innovations in stroke prevention and disparities in care, this episode delves into pivotal studies shaping the future of cardiology and their real-world clinical implications.

JACC - November 19, 2024 Issue Summary Nov 11, 2024

In the November 19, 2024, issue of JACC, Dr. Valentin Fuster discusses four groundbreaking studies that could shape the future of cardiovascular care. Topics include the impact of atrial fibrillation screening on stroke prevention, risk factors in Brugada syndrome, new methods to reduce heart block after congenital heart disease surgery, and genetic insights into arrhythmogenic triggers of atrial fibrillation, alongside a review of a decade of leadless cardiac pacing technology.

Screening for Undiagnosed Atrial Fibrillation and Stroke Prevention Nov 11, 2024

In this episode, Dr. Valentin Fuster discusses the Garter AF trial, which evaluates the impact of screening for undiagnosed atrial fibrillation (AF) in older adults using a 14-day ECG monitor to reduce stroke risk. While the study found a marginal increase in AF diagnoses, it suggests that AI could play a crucial role in identifying high-risk patients who would benefit most from such screenings, highlighting the need for a more targeted approach in future trials.

Non-Modifiable Risk Factors Predict Outcomes in Brugada Syndrome Nov 11, 2024

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on Brugada Syndrome, exploring how non-modifiable risk factors—such as male sex, SCN 5A mutations, and polygenic risk scores—can predict life-threatening arrhythmic events in patients. The research, published in JACC (November 2024), offers new insights into personalized risk assessment for this inherited arrhythmia syndrome, though its clinical implications remain limited for now.

Intraoperative Conduction Mapping to Reduce Postoperative Atrioventricular Block in Complex Congenital Heart Disease Nov 11, 2024

In this podcast, Dr. Valentin Fuster reviews a groundbreaking study on intraoperative conduction mapping to prevent postoperative atrioventricular block (AVB) in children with complex congenital heart disease. The study highlights how mapping the His bundle during surgery significantly reduces the need for pacemakers, particularly in high-risk populations like those with Heterotaxy syndrome and non-Transposed Great Arteries, offering a promising tool to improve long-term outcomes for these patients.

Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation Nov 11, 2024

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on the embryological origins of atrial fibrillation triggers, which could help refine treatment strategies for the condition. The research highlights how genetic factors linked to specific atrial regions, like the sinus venosus and primitive atrium, influence arrhythmia recurrence after ablation, potentially paving the way for more personalized, effective treatments.

Ten Years of Leadless Cardiac Pacing Nov 11, 2024

In this episode, Dr. Valentin Fuster explores the evolution of leadless cardiac pacing over the past decade, highlighting its safety, efficacy, and growing role in treating heart patients. He reviews key advancements, including single and dual-chamber leadless pacemakers, ongoing innovations, and future developments, emphasizing their potential to replace traditional pacemakers and improve patient outcomes.

JACC - November 12, 2024 Issue Summary Nov 04, 2024

In this episode, Dr. Valentin Fuster highlights the groundbreaking studies featured in the November 12, 2024 issue of the JACC, focusing on the emerging role of proteomics in understanding heart failure and hypertrophic cardiomyopathy. He discusses key findings on SGLT2 inhibitors, the efficacy of complete revascularization in myocardial infarction patients, and novel treatments for hypercholesterolemia, emphasizing the transformative potential of these insights for cardiovascular care.

Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Heart Failure: a EMPEROR Validation Cohort Nov 04, 2024

In this episode, Dr. Valentin Fuster discusses groundbreaking research on SGLT2 inhibitors and their impact on heart failure, highlighting the validation of mechanistic proteomic signatures from a major clinical trial. The study reveals how empagliflozin influences over 2,000 proteins, promoting autophagy, enhancing mitochondrial health, and normalizing kidney function, offering new insights into therapeutic strategies for heart failure management.

Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy Nov 04, 2024

In this episode, Dr. Valentin Fuster discusses groundbreaking research on hypertrophic cardiomyopathy (HCM), revealing dysregulated signaling pathways through comprehensive proteomic profiling of human myocardial tissue. The study identifies novel therapeutic targets, including the Ras MAPK pathway and the ubiquitin-proteasome system, while emphasizing the need for further exploration beyond obstructive cases to better understand the disease's molecular mechanisms.

Complete vs. Culprit-Only Revascularization in Older Patients with Myocardial Infarction with or without ST-segment elevation Nov 04, 2024

In this episode, Dr. Valentin Fuster discusses a pivotal study on revascularization strategies in older patients with myocardial infarction, comparing complete versus culprit-only approaches. The findings suggest that physiology-guided complete revascularization significantly reduces adverse outcomes in both STEMI and non-STEMI patients, emphasizing its potential benefits across a diverse patient population.

Recaticimab Monotherapy for Non-Familial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial Nov 04, 2024

In this episode, Dr. Valentin Fuster reviews two pivotal phase three trials from China assessing the efficacy of the new monoclonal antibody, Katisha, for treating non-familial hypercholesterolemia. With significant reductions in LDL cholesterol and a long-acting, flexible dosing regimen, these studies promise a novel therapeutic option for patients struggling with cholesterol management and adherence to traditional treatments.

Recaticimab as add-on therapy to statins for non-familial hypercholesterolaemia: the phase 3 REMAIN-2 trial Nov 04, 2024

In this episode, Dr. Valentin Fuster reviews two pivotal phase three trials from China assessing the efficacy of the new monoclonal antibody, Katisha, for treating non-familial hypercholesterolemia. With significant reductions in LDL cholesterol and a long-acting, flexible dosing regimen, these studies promise a novel therapeutic option for patients struggling with cholesterol management and adherence to traditional treatments.

Artificial Intelligence in Cardiovascular Clinical Trials Nov 04, 2024

In this episode, Dr. Valentin Fuster delves into the transformative potential of artificial intelligence (AI) in cardiovascular clinical trials, guided by a comprehensive review from leading experts. Highlighting both innovative applications and regulatory challenges, the discussion emphasizes AI's role in trial design, patient recruitment, and data analysis, while cautioning against risks like bias and data privacy concerns.

Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs. Second-Generation DES: TARGET-IV NA Trial Oct 30, 2024

Author Robert W. Yeh, MD, FACC, and JACC Associate Editor Celina M. Yong, MD, FACC, discuss the results of the TARGET-IV NA trial. In the trial, 1720 patients with stable or acute coronary syndromes were randomized to undergo PCI with a BP-SES or any commonly used 2nd generation DES. At 12 months, BP-SES was non-inferior to control DES for the primary endpoint of Target Lesion Failure (cardiac death, target vessel-related myocardial infarction (MI), or ischemia-driven target lesion revascularization) which occurred in 3.4% of the BP-SES arm versus 3.3% in the control arm; p-value for non-inferiority. Secondary endpoints were also similar between groups.

Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial Oct 30, 2024

In this episode of JACC, Author Suzanne Arnold, MD and JACC Associate Editor Dennis T. Ko, MD, discusses groundbreaking findings from the Tricatin-2 trial, the first clinical study on transcatheter tricuspid valve replacement. The results reveal significant improvements in quality of life for patients, particularly those with severe tricuspid regurgitation, highlighting the transformative potential of this procedure compared to traditional medical therapy.

Drug-Coated Balloon Angioplasty Of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial Oct 28, 2024

Author Shao-Liang Chen, MD, FACC, and JACC Associate Editor Celina M. Yong, MD, FACC, discuss patients with simple and true coronary bifurcation lesions undergoing provisional stenting. Main vessel stenting with a DCB for the compromised side branch resulted in a lower 1-year rate of the composite outcome compared with an NCB intervention for the side branch. The high rates of periprocedural myocardial infarction, which occurred early and did not lead to revascularization, are of unclear clinical significance.

Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD Oct 28, 2024

Author Nicolas M. Van Mieghem, MD, PhD, FACC, and JACC: Executive Associate Editor Aakriti Gupta, MD, FACC, discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

JACC - November 5, 2024 Issue Summary Oct 28, 2024

In the November 5, 2024 issue of JACC, Dr. Valentin Fuster summarizes the November 5, 2024 issue of the JACC, which focuses exclusively on hypertrophic cardiomyopathy (HCM). Highlighting six original research papers, the discussion emphasizes the groundbreaking impact of the cardiac myosin inhibitor Aficamten on health outcomes, symptom burden, and cardiac structure in patients with obstructive HCM, while also exploring genetic screening implications for affected families.

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM Oct 28, 2024

In this episode, Dr. Valentin Fuster delves into the latest research on hypertrophic cardiomyopathy, highlighting the significant health status improvements achieved with the new cardiac myosin inhibitor, Aficamten, compared to placebo. The findings from the Sequoia HCM study reveal that Aficamten markedly enhances patients' quality of life and alleviates symptoms like chest pain and shortness of breath, paving the way for more effective treatments in this challenging condition.

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy Oct 28, 2024

In this episode, Dr. Valentin Fuster explores groundbreaking research on hypertrophic cardiomyopathy, focusing on the effects of the drug aficamten on cardiac structure and function. Highlighting significant findings from the Sequoia HCM trial, the discussion underscores the potential of aficamten to induce favorable cardiac remodeling and improve patient outcomes, signaling a transformative era in the management of this condition.

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy Oct 28, 2024

In this episode, Dr. Valentin Fuster delves into a groundbreaking study on the effects of the cardiac myosin inhibitor, Aficamten, on patients with obstructive hypertrophic cardiomyopathy. The findings reveal significant improvements in echocardiographic measures of cardiac function, despite a mild and reversible decrease in left ventricular ejection fraction, highlighting the need for long-term safety evaluations of this promising treatment.

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM Oct 28, 2024

In this episode, Dr. Valentin Fuster introduces a dedicated focus on hypertrophic cardiomyopathy, featuring a pivotal study by Dr. Martin Maron and Dr. lacopo Olivotto on the impact of aficamptin. This pre-specified sub-analysis from the SEQUOIA HCM trial aims to comprehensively evaluate the drug's effects on various aspects of disease burden, enhancing our understanding of its clinical efficacy.

Standard of Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM Oct 28, 2024

In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.

Family Screening in Hypertrophic Cardiomyopathy - Identification of Relatives with Low Yield from Systematic Follow-up Oct 28, 2024

In this episode, Dr. Valentin Fuster dives into a pivotal study on hypertrophic cardiomyopathy, focusing on the challenges of identifying at-risk relatives when genetic variants are not found in 60% of families. With insights into the disease's autosomal dominant inheritance and incomplete penetrance, this discussion highlights the complexities of family screening and the need for innovative approaches in managing this condition.

Transcatheter Valve Repair for Tricuspid Regurgitation: 1-Year Results From a Large European Real-World Registry Oct 27, 2024

Author Joerg Hausleiter, MD and Executive Associate Editor Aakriti Gupta, MD, FACC. discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-year Outcomes From the TRILUMINATE Randomized Cohort Oct 27, 2024

JACC Associate Editor Celina M. Yong, MD, FACC, and JACC: Case Reports Editor in Chief Gilbert H. L. Tang, MD, MSc, MBA, FACC, discuss this paper published in JACC and presented at TCT. TRILUMINATE Pivotal is the first randomized, controlled trial evaluating transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR). Adaptive design randomized 572 subjects in the primary or subsequent cohorts. Subjects were elderly with atrial fibrillation and prior HFH. Primary endpoint was met at 1 year with a larger win ratio for T-TEER driven by KCCQ improvement with no significant differences in mortality and tricuspid valve surgery or HFH.

JACC - October 29, 2024 Issue Summary Oct 21, 2024

In the October 29, 2024 issue of JACC, Dr. Valentin Fuster explores groundbreaking studies on heart failure treatments, including the impact of sacubitril-valsartan on hypotension, the benefits of intravenous iron for reducing hospitalizations, the prognostic value of platelet FCγRIIA in post-myocardial infarction patients, and innovative AI assessments of environmental factors influencing cardiovascular risk.

Asymptomatic versus symptomatic hypotension with sacubitril/valsartan in heart failure and reduced ejection fraction in PARADIGM-HF Oct 21, 2024

In this episode, researchers explore how asymptomatic versus symptomatic hypertension affects heart failure patients on sacubitril valsartan, finding that both types are linked to worse outcomes, but the drug’s benefits remain strong, suggesting clinicians should avoid stopping treatment based solely on blood pressure.

The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Oct 21, 2024

In this episode, Dr. Valentin Fuster reviews the Ironman trial, which studied the effects of intravenous iron on patients with heart failure and iron deficiency. While intravenous iron improved symptoms and reduced recurrent hospitalizations, it did not significantly impact first-time hospitalizations or mortality rates, suggesting the need for further research into its broader clinical benefits.

FcγRIIa: A Marker of Cardiovascular Risk after Myocardial Infarction Oct 21, 2024

In this episode, Dr. David J. Schneider research identifies platelet FCγRIIA (PFCG) as a key biomarker for cardiovascular risk post-myocardial infarction. In an 800-patient study, higher PFCG levels were linked to increased risks of myocardial infarction, stroke, and death, indicating its potential for guiding personalized antiplatelet therapy, pending further validation.

AI-Facilitated Assessment of Built Environment Using Neighborhood Satellite Imagery and Cardiovascular Risk Oct 21, 2024

In this episode, Dr. Zhuo Chen and his team explore how AI-driven analysis of neighborhood satellite imagery can reveal links between the built environment and cardiovascular risk. Their findings suggest that while AI can predict adverse cardiovascular events, the influence of social determinants, particularly socioeconomic status, plays a critical role in this relationship, underscoring the need for further research into these complex interactions.

Aspirin Hypersensitivity in Patients with Atherosclerotic Cardiovascular Disease Oct 21, 2024

In this episode, Dr. Valentin Foster introduces a vital review on aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease, led by Dr. Mattia Galli and Dr. Dominick J. Angiolillo. The discussion spans the history, epidemiology, and mechanisms of aspirin hypersensitivity, alongside strategies for management and practical recommendations for healthcare providers.

JACC - October 22, 2024 Issue Summary Oct 14, 2024

In this episode, Dr. Valentin Fuster summarizes the pivotal October 2024 issue of the JACC Journal, focusing on the intersection of obesity and cardiology. Key discussions include the revolutionary impact of anti-obesity medications like semaglutide on heart health, the intricate relationship between obesity and heart failure with preserved ejection fraction, and the urgent need for equitable access to these therapies for improved cardiovascular outcomes.

Effect of Semaglutide on Cardiac Structure and Function in Patients with Obesity-Related Heart Failure Oct 14, 2024

In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function, attenuates adverse remodeling, and showcases the dual mechanisms—both weight-related and independent—behind these effects.

Atrial fibrillation and semaglutide efficacy in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF Program Oct 14, 2024

In this episode, Dr. Valentin Foster highlights the October 2024 issue of JACC, which delves into the benefits of semaglutide for obesity-related heart failure with preserved ejection fraction. A key study presented shows that semaglutide significantly improves heart failure symptoms and physical limitations, particularly in patients with a history of atrial fibrillation, underscoring its efficacy beyond mere weight loss.

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease (FLOW Trial) Oct 14, 2024

In this episode, Dr. Valentin Foster explores the October issue of JACC, which highlights obesity and the potential benefits of glucagon-like peptide receptor agonists, particularly semaglutide, in treating heart failure. He delves into the FLOW trial, revealing how semaglutide significantly reduced heart failure events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease, while also addressing the study's limitations and the need for improved diagnostic criteria in future research.

The Effect of Semaglutide on Mortality and COVID-19-Related Deaths - An Analysis From the SELECT Trial Oct 14, 2024

In this episode, Dr. Valentin Foster explores the October 2024 issue of JACC, highlighting the significant benefits of semaglutide, particularly for individuals with obesity and cardiovascular disease. He focuses on findings from the SELECT trial, which demonstrate that semaglutide reduces overall and cardiovascular mortality, as well as COVID-19 related deaths, emphasizing the need for continued innovative research in addressing health challenges.

Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program Oct 14, 2024

In this episode, Dr. Valentin Fuster discusses a pivotal study on inflammation's role in obesity-related heart failure with preserved ejection fraction, highlighting findings from the STEP heart failure program. The research reveals that semaglutide improves heart failure symptoms and reduces inflammation across varying baseline CRP levels, suggesting cardiovascular benefits that extend beyond weight loss alone.

JACC - The Effect of Teleprehabilitation on Adverse Events After Elective Cardiac Surgery: A Randomized Controlled Trial | EACTS 2024 Oct 11, 2024

Dr. Sardari Nia's trial on digital cardiac counseling, presented at EACTS and published in JACC, is a randomized study of 394 patients. It investigated the impact of telemedicine-based prehabilitation to reduce modifiable risk factors in patients awaiting elective cardiac surgery. The results demonstrated a significant 35% reduction in major adverse events, particularly rehospitalizations, highlighting the safety and effectiveness of prehabilitation in improving patient outcomes. This trial also emphasizes empowering patients to take control of their health before surgery, potentially benefiting healthcare on a larger scale.

JACC - October 15, 2024 Issue Summary Oct 07, 2024

In this episode, Dr. Valentin Fuster summarizes the October 2024 issue of the JACC Journal, highlighting four pivotal studies on atrial fibrillation, anticoagulation strategies in STEMI, heart failure risk assessment, and the impact of urinary metal levels on coronary artery calcification. Emphasizing the increasing prevalence of atrial fibrillation and the critical role of biomarkers, he underscores the urgent need for enhanced prevention strategies and public health actions regarding environmental metal exposure.

Minimum National Prevalence of Diagnosed Atrial Fibrillation inferred from California Acute Care Facilities Oct 07, 2024

In the October 15, 2024, issue of JACC, Dr. Valentin Fuster highlights a crucial study revealing that the prevalence of diagnosed atrial fibrillation in the U.S. has surged to at least 10.5 million adults, driven by factors like aging, obesity, and diabetes. With a call for improved prevention and treatment strategies, experts stress the urgent need for public health initiatives to tackle this growing burden on the healthcare system.

Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results Oct 07, 2024

In this episode, Dr. Valentin Fuster discusses a pivotal study comparing bivalirudin and heparin anticoagulation in STEMI patients undergoing primary PCI, highlighting that bivalirudin may reduce cardiac mortality and bleeding without increasing thrombotic events. While the findings challenge previous guidelines favoring heparin, limitations in the research prompt caution about immediate changes to clinical practice, emphasizing the need for further exploration of bivalirudin's role in diverse patient populations.

Heart failure risk assessment using biomarkers in patients with atrial fibrillation: Analysis from COMBINE-AF Oct 07, 2024

In the October 15, 2024 issue of JACC, a study led by Dr. Paul Haller investigates the use of biomarkers—NT-proBNP, high-sensitive cardiac troponin T, and GDF-15—to assess heart failure risk in patients with atrial fibrillation. The findings reveal that these biomarkers significantly enhance risk stratification, suggesting their potential to identify patients at varying risks for heart failure and improve clinical management.

Urinary Metal Levels and Coronary Artery Calcification: Longitudinal Evidence in the Multi-Ethnic Study of Atherosclerosis Oct 07, 2024

In this episode, Dr. Valentin Fuster discusses a groundbreaking study linking urinary metal levels, particularly non-essential metals like cadmium and uranium, to coronary artery calcification, highlighting their potential role in cardiovascular disease. The findings underscore the urgent need for public health initiatives to address environmental metal exposure, as they could significantly mitigate cardiovascular risks and health disparities.

International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence. Oct 07, 2024

In this insightful episode of JACC, Dr. Valentin Fuster summarizes groundbreaking international clinical practice guidelines for acute pulmonary embolism, authored by Dr. Marco Suin and colleagues. The discussion delves into key aspects such as diagnosis, risk stratification, immediate anticoagulation, and advanced therapies, highlighting the challenges and recommendations that can ultimately guide clinicians in managing this critical condition.

Part Two: Time to Significant Benefit of Finerenone in Patients With Heart Failure | JACC | HFSA 2024 Oct 04, 2024

Michelle M Kittleson, MD, FACC, JACC Associate Editor, speaks with author Muthiah Vaduganathan, MD on his accepted paper concerning the FINEARTS trial published in JACC.

Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial | JACC | HFSA 2024 Oct 04, 2024

Akshay S. Desai, MD, FACC presents his accepted HFSA presentation concerning the FINEARTS trial published in JACC, with commentary by Theresa McDonagh, MBBCH, JACC Associate Editor.

JACC - October 8, 2024 Issue Summary Sep 30, 2024

In this episode, Dr. Valentin Fuster highlights groundbreaking research from the October 8, 2024 issue of JACC. Key studies delve into the evolving diagnostic criteria for myocarditis, the prognostic value of subclinical atherosclerosis, the arrhythmic risks in non-ischemic cardiomyopathy, and the implications of PFO closure on ischemic stroke risk, underscoring the importance of advanced imaging techniques and clinical criteria in modern cardiovascular care.

Prognostic Implications of Clinical- and Imaging Diagnostic Criteria for Myocarditis Sep 30, 2024

In the October 8, 2024 issue of JACC, a pivotal study explores the prognostic implications of various diagnostic criteria for myocarditis, comparing the European Society of Cardiology and the late-luis criteria. The findings reveal that while most patients can be diagnosed using ESC criteria, the combination of both sets enhances risk stratification, emphasizing the need for collaboration between clinical cardiologists and imaging specialists in managing suspected myocarditis cases.

Influence of subclinical atherosclerosis burden and progression on mortality Sep 30, 2024

In this episode, Dr. Valentin Fuster discusses groundbreaking research on the impact of subclinical atherosclerosis on mortality, revealing insights from a 15-year study. He emphasizes the limitations of traditional cardiovascular risk prediction tools, like the Framingham Risk Score, and calls for deeper exploration of individual risk factors for better long-term outcomes.

Arrhythmic Risk Stratification by Cardiovascular Magnetic Resonance Imaging in Patients with Non-ischemic Cardiomyopathy Sep 30, 2024

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that evaluates the role of myocardial fibrosis in predicting sudden cardiac death and ventricular arrhythmias in patients with non-ischemic cardiomyopathy. The findings suggest that assessing fibrosis through advanced imaging techniques offers a more accurate risk stratification than the traditional reliance on left ventricular ejection fraction, ultimately refining treatment approaches for at-risk patients.

Risk of Ischemic Stroke After Patent Foramen Ovale Closure Sep 30, 2024

In the October 8, 2024, issue of JACC, Dr. Casper Bonison and colleagues present a study on the risks of ischemic stroke recurrence after PFO closure, revealing that while the four-year risk remains higher than the general population, it mirrors clinical trial findings. They emphasize the importance of careful patient selection and the need for further research into closure techniques and associated stroke risk factors.

Contemporary Training in American Critical Care Cardiology: Minnesota Critical Care Cardiology Education Summit Sep 30, 2024

In this episode, Dr. Valentin Fuster introduces a crucial consensus document on Critical Care Cardiology training, highlighting insights from leading experts at the University of Minnesota and Harvard. With the field rapidly expanding and 20% of incoming cardiology fellows expressing interest in this specialty, the panel outlines key recommendations for enhancing training programs to meet evolving demands.

ACC/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2024 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Nonemergent, Noncardiac Surgery Sep 30, 2024

In this episode, experts discuss a crucial 2024 document outlining appropriate use criteria for multimodality imaging in cardiovascular evaluation before non-emergent non-cardiac surgery, addressing the rising annual surgeries and associated cardiac risks. They delve into balancing the necessity of imaging with cost-effectiveness while exploring the potential of artificial intelligence to enhance future evaluations.

Time to Significant Benefit of Finerenone in Patients with Heart Failure | HFSA 2024 Sep 28, 2024

Michelle M Kittleson, MD, FACC, JACC Associate Editor, speaks with author Muthiah Vaduganathan, MD on his accepted paper concerning the FINEARTS trial published in JACC.

JACC - October 1, 2024 Issue Summary Sep 23, 2024

In the October 2024 issue of JACC, Dr. Valentin Fuster highlights five diverse studies addressing key topics in cardiovascular health, from surgical outcomes for congenital anomalies to the impact of patiromer on heart failure therapies. The episode underscores the importance of managing cardiovascular risk factors in chronic kidney disease and explores new insights into lipid profiles, revealing that triglyceride-rich lipoproteins may pose greater cardiovascular risks than previously understood.

Outcomes of Patients Undergoing Surgery for Complete Vascular Rings Sep 23, 2024

In this episode, Dr. Valentin Fuster highlights a groundbreaking study on surgical outcomes for complete vascular rings, revealing that 95% of children experience complete symptom resolution after comprehensive surgical interventions. The discussion emphasizes the evolution of surgical techniques at Boston Children's Hospital and the potential for fetal diagnosis to alter the natural history of this congenital anomaly.

Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients with Heart Failure and Hyperkalemia Sep 23, 2024

In this episode, Dr. Valentin Foster highlights a groundbreaking study published in the October 2024 issue of JACC, which explores how patiromer facilitates the effective use of angiotensin inhibitors and mineralocorticoid antagonists in heart failure patients at risk of hyperkalemia. Authored by Dr. Bertram Pete and colleagues, the research demonstrates that patiromer not only helps achieve optimal medication doses but also improves potassium management, ultimately enhancing patient outcomes in this high-risk population.

Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, and Mortality in Chinese Adults Sep 23, 2024

In this episode, Dr. Valentin Fuster discusses groundbreaking research on the interplay between cardiovascular risk factors and chronic kidney disease (CKD) progression among Chinese adults. Highlighting a study that reveals how effective management of hypertension, cholesterol, and blood glucose can significantly reduce the risks of cardiovascular events and mortality in CKD patients, the conversation emphasizes the crucial need for targeted treatment strategies to improve patient outcomes.

Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol Sep 23, 2024

In this insightful discussion from the October 1, 2024 issue of JACC, researchers reveal that triglyceride-rich lipoprotein (TRL) remnants are significantly more atherogenic than LDL cholesterol, suggesting a need for updated risk assessment strategies. The study advocates for a shift towards evaluating lipoproteins on a per-particle basis, which could revolutionize the diagnosis and treatment of lipid disorders by focusing on the functional activity of these particles.

Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients with Overt Chronic Kidney Disease: JACC State-of-the-Art Review Sep 23, 2024

In this episode, Dr. Valentin Fuster discusses a comprehensive review on the challenges and considerations of using implantable cardiography devices in patients with advanced chronic kidney disease and heart failure. Highlighting key findings from Dr. Cecilia Barca's research, he explores the nuanced interplay between these conditions and device efficacy, emphasizing the need for tailored patient evaluations and future studies to improve outcomes.

2024 ACC/AHA Key Data Elements and Definitions for Social Determinants of Health in Cardiology Sep 23, 2024

In this episode, Dr. Valentin Fuster reviews a pivotal document on Social Determinants of Health (SDOH) in cardiology, highlighting their critical role in shaping health outcomes. He outlines ten key insights, emphasizing the need for standardized definitions and integration of SDOH into electronic health records to promote equitable healthcare and improve patient outcomes.

Urinary Metal Levels and Coronary Artery Calcification: Longitudinal Evidence in the Multi-Ethnic Study of Atherosclerosis Sep 20, 2024

Dr. Kaitlyn McGraw discusses her study on the relationship between urinary trace metal levels and coronary artery calcification, highlighting the role of environmental exposures in cardiovascular disease risk. The research reveals significant associations between elevated levels of metals like cadmium, tungsten, and uranium with the progression of calcification, comparable to traditional risk factors such as smoking and diabetes. Dr. McGraw emphasizes the need for integrating environmental factors into cardiovascular risk assessments and suggests policy changes to better regulate metal exposure in the population. Moderated by Khurram Nasir, MBBS, FACC.

JACC - September 24, 2024 Issue Summary Sep 16, 2024

In this episode, Dr. Valentin Fuster highlights key studies from the September 24, 2024 issue of JACC, featuring groundbreaking research on the impact of cold temperatures on myocardial infarctions, the nuanced recovery process in Takotsubo syndrome, and evolving trends in the condition. Also discussed are novel insights into predicting long-term outcomes for recurrent pericarditis and the influence of obstructive sleep apnea on cardiovascular health.

Short-term effects of lower air temperature and cold spells on myocardial infarction hospitalizations in Sweden Sep 16, 2024

In the September 24, 2024 issue of JACC, Dr. Ben Lee Nay and colleagues reveal that short-term exposures to lower temperatures and cold spells significantly increase the risk of myocardial infarction hospitalizations in Sweden. This nationwide study, utilizing advanced machine learning techniques, underscores the pressing need to address both extreme cold and heat in climate change mitigation efforts to better protect cardiovascular health.

Recovery of Left Ventricular Function and Long-term Outcomes in Patients with Takotsubo Syndrome Sep 16, 2024

In the September 24, 2024 issue of JACC, Dr. Manuel Almendro Odelia and Dr. Ivan Nunet Hill present groundbreaking research on Takotsubo syndrome, revealing that delayed recovery of left ventricular function significantly worsens both short and long-term survival. The study, based on data from the extensive RITACCO registry, identifies key predictors of slow recovery and underscores the need for closer follow-up in affected patients, challenging traditional treatment approaches and highlighting the evolving understanding of this complex condition.

Temporal Trends in Takotsubo Syndrome - Results from the International Takotsubo Registry Sep 16, 2024

In the September 24, 2024 issue of JACC, Dr. Valentin Fuster explores a pivotal study on Takotsubo Syndrome, revealing significant shifts in patient demographics, trigger types, and outcomes over nearly two decades. The research highlights an increase in physical triggers and short-term mortality, reflecting a more complex and severe understanding of the condition than previously recognized.

Predicting Long-term Clinical Outcomes of Patients with Recurrent Pericarditis Sep 16, 2024

In the September 24, 2024, issue of JACC, Dr. Abdullah Yashin Yaprak and his team at Cleveland Clinic unveil a groundbreaking risk prediction model for recurrent pericarditis using machine learning. Their study, analyzing data from 365 patients, offers a novel tool to stratify patients based on their likelihood of achieving clinical remission, showcasing the promising intersection of AI and personalized medicine in cardiology.

2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee Sep 16, 2024

In the September 24, 2024, JACC issue, Dr. Valentin Fuster presents the latest expert consensus on heart failure management, updating the 2019 guidelines with ten key changes. Highlights include a strong emphasis on SGLT inhibitors throughout hospitalization and a refined approach to managing heart failure patients, ensuring timely adjustments in therapy and improved patient care strategies.

Interactions of Sleep Apnea with the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review Sep 16, 2024

In this episode, Dr. Valentin Fuster dives into a comprehensive review of obstructive sleep apnea, exploring its complex interactions with cardiovascular disease and discussing its multifaceted treatment options. The podcast unpacks how sleep apnea exacerbates cardiovascular conditions through biological pathways, examines the impact of various therapies, and considers future directions for research and clinical practice.

JACC - September 17, 2024 Issue Summary Sep 09, 2024

In this episode, Valentin Fuster reviews the September 17, 2024, JACC issue, highlighting pivotal studies on metabolic surgery's impact on cardiovascular risk in obstructive sleep apnea patients, and the potential of DPP-4 inhibitors in aortic valve calcification. He also discusses the benefits of Sitagliptin for heart failure and the prognostic value of plasma immunoglobulins in pulmonary arterial hypertension, closing with a look at genotype-guided antiplatelet therapy.

Adverse Cardiovascular Outcomes in Patients with Obstructive Sleep Apnea and Obesity: Metabolic Surgery versus Usual Care Sep 09, 2024

In this episode, Dr. Valentin Fuster reviews a groundbreaking study comparing metabolic surgery to traditional care for patients with obesity and obstructive sleep apnea. The research shows that metabolic surgery significantly lowers the risk of major cardiovascular events and mortality, highlighting the need for a multifaceted approach to treating these interlinked conditions.

Effect of Evogliptin on the Progression of Aortic Valvular Calcification Sep 09, 2024

In the September 17, 2024 issue of JACC, Dr. Jai Quan Song and colleagues explore whether the DPP-4 inhibitor, abrogating, can slow the progression of aortic valvular calcification. Although the primary endpoint was not met, the study's promising secondary results and ongoing research into related therapies suggest potential future breakthroughs in medical treatment for aortic stenosis.

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF Sep 09, 2024

In the September 17, 2024 issue of JACC, Valentin Fuster discusses a study on sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, which shows modest improvements in health status among patients with worsening heart failure. While the study highlights sotagliflozin's benefits, it also points out gaps in understanding its full impact and emphasizes the need to optimize current treatments and explore future interventions.

Prognostic value of plasma IgG N-glycome traits in pulmonary arterial hypertension Sep 09, 2024

In this September 17, 2024 JACC issue, Dr. Zhi Jian Zhang and colleagues unveil a groundbreaking study on pulmonary arterial hypertension (PAH) that identifies plasma IgG fucosylation and glycan traits as promising prognostic markers. This research not only enhances survival predictions beyond current models but also opens intriguing possibilities for future therapeutic targets in PAH.

Genotype Guided Antiplatelet Therapy: JACC Review Topic of the Week Sep 09, 2024

In this episode of JACC, Valentin Fuster examines genotype-guided antiplatelet therapy, emphasizing its potential to tailor treatments based on genetic variants for improved patient outcomes. While promising, the approach faces challenges like testing delays and variable patient responses that need addressing for broader implementation.

RESHAPE-HF2 Trial Findings | ESC 2024 Sep 06, 2024

Dr. Marcus Anker, presenting at ESC, discussed the RESHAPE HF2 trial's findings on transcatheter edge-to-edge repair for secondary mitral regurgitation, published in JACC with Aakriti Gupta, MD, FACC, JACC Executive Associate Editor.

Effect of Screening for Undiagnosed Atrial Fibrillation and on Stroke Prevention | ESC Congress Sep 05, 2024

Xiaoxi Yao, MPH, MS, PhD, FACC, JACC Associate Editor, interviews Renato Lopes, MD, PhD, FACC, author of the GUARD-AF trial published in JACC and presented at ESC Congress 2024.

Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024 Sep 03, 2024

Michelle M. Kittleson, MD, PhD, FACC, JACC Associate Editor and John A. Spertus, MD, MPH, FACC discuss the evaluation of the cardiac myosin inhibitor, aficamten, on patient-reported health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) as part of the SEQUOIA trial. The study utilized the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score (OSS) and the Seattle Angina Questionnaire to assess the broader impact of the disease and treatment on patients' lives, emphasizing symptoms, function, and quality of life. The findings highlight the significance of these tools in capturing meaningful patient outcomes, beyond traditional physiological measures, which can guide clinicians in counseling HCM patients about treatment expectations. The rapid decline in health status after discontinuation of aficamten underscores its potential importance in managing HCM.

Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024 Sep 03, 2024

Michelle M. Kittleson, MD, PhD, FACC, JACC Associate Editor and John A. Spertus, MD, MPH, FACC discuss the evaluation of the cardiac myosin inhibitor, aficamten, on patient-reported health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) as part of the SEQUOIA trial. The study utilized the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score (OSS) and the Seattle Angina Questionnaire to assess the broader impact of the disease and treatment on patients' lives, emphasizing symptoms, function, and quality of life. The findings highlight the significance of these tools in capturing meaningful patient outcomes, beyond traditional physiological measures, which can guide clinicians in counseling HCM patients about treatment expectations. The rapid decline in health status after discontinuation of aficamten underscores its potential importance in managing HCM.

JACC - September 10, 2024 Issue Summary Sep 02, 2024

In the September 10, 2024, issue of JACC, Dr. Valentin Fuster highlights groundbreaking research on lipid exposure in early adulthood and its link to later cardiovascular events, the importance of early and serial assessments in cardiogenic shock, and the impact of triglyceride levels on cardiovascular outcomes with alirocumab. He also discusses the association between postnatal opioid exposure and neurodevelopmental outcomes in infants undergoing cardiac surgery, alongside a brief update on the long-term benefits of Mercantor in obstructive hypertrophic cardiomyopathy.

Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood Sep 02, 2024

In the September 10, 2024, JACC issue, Dr. Valentin Fuster highlights a pivotal study showing that a single cholesterol measurement in young adults can predict future cardiovascular risk with remarkable accuracy. He underscores the need for early lipid screening and novel long-acting treatments to improve long-term cardiovascular health, stressing that early intervention is crucial for preventing future heart disease.

Serial Shock Severity Assessment Within Seventy-Two Hours after Diagnosis: A Cardiogenic Shock Working Group Report Sep 02, 2024

In the September 10, 2024, JACC issue, Dr. Valentin Fuster discusses a pivotal study on cardiogenic shock, revealing that early and frequent reassessment within the first 24 hours is crucial for predicting patient outcomes. The study underscores the critical nature of early intervention and highlights the rapid progression seen in many patients, emphasizing the need for timely and continuous monitoring to improve survival rates.

Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome Sep 02, 2024

In the September 10, 2024, issue of JACC, the study by Dr. Doron Seeker and colleagues investigates alirocumab’s impact on cardiovascular outcomes related to triglyceride levels. Despite effectively lowering LDL cholesterol, alirocumab did not show significant clinical benefit through triglyceride reduction, suggesting that its efficacy may be limited in addressing cardiovascular risk associated with elevated triglycerides.

Association of Postnatal Opioid Exposure and 2-year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery Sep 02, 2024

In this September 10th, 2024 issue of Jack, Dr. Michael Ogburn's study highlights a troubling association between high postnatal opioid exposure and poorer neurodevelopmental outcomes in infants who have undergone cardiac surgery. Despite careful adjustments for confounding factors, increased opioid use was linked to significant deficits in cognitive, language, and motor skills, emphasizing the need for stricter protocols and alternative pain management strategies in pediatric cardiac care.

Serial Shock Severity Assessment: Some Answers. Still Many Questions. | ESC 2024 Aug 31, 2024

Rasha K. Al-Lamee, MD, PhD, JACC Deputy Editor and Navin K. Kapur MD discuss the work from the Cardiogenic Shock Working Group, which is an academic research consortium comprising ~40 hospitals in the U.S. and internationally.

Insights from RESHAPE-HF2 Trial | ESC 2024 Aug 31, 2024

Aakriti Gupta, MD, FACC, JACC Executive Associate Editor, and Stefan D. Anker, MD, discuss the insights from the RESHAPE-HF2 trial - an eight-year study on the efficacy of transcatheter edge-to-edge repair for mitral valve regurgitation in patients with heart failure.

A Secondary Analysis of DANFLU-1 Trial - High vs Standard Dose Influenza Vaccine in CKD | ESC 2024 Aug 31, 2024

Khurram Nasir, MBBS, FACC, JACC Associate Editor and Tor Biering-Sorenson, MD, MPH, PhD, discuss the importance of influenza vaccines for patients with chronic kidney disease (CKD), particularly in the context of the DANFLU-1 study.

Updates from the STEP-HFpEF Trial | ESC 2024 Aug 30, 2024

Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Mikhail Kosiborod, MD, FACC discuss an exciting secondary analysis of the STEP-HFpEF program, shedding light on the groundbreaking findings related to heart failure and obesity.

Updates from the SELECT Trial: Outcomes by Sex | ESC 2024 Aug 30, 2024

Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating the cardiovascular benefits of semaglutide in people with obesity or overweight without diabetes.

An Analysis From the SELECT Trial - COVID-19| ESC 2024 Aug 30, 2024

Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT trial, which investigated the effects of semaglutide on COVID-19 outcomes and non-cardiovascular deaths in patients with obesity and cardiovascular disease.

Insights from the FLOW Trial | ESC 2024 Aug 30, 2024

Neha J. Pagidipati, MD, FACC, JACC Associate Editor, and Richard Pratley, MD, discuss insights from the FLOW trial – revealing that semaglutide reduced heart failure events and cardiovascular death by approximately 27%, both in patients with and without prior heart failure.

JACC - September 3, 2024 Issue Summary Aug 26, 2024

In this episode, Dr. Valentin Fuster reviews five pivotal studies from September 2024, focusing on antithrombotic strategies and diabetes treatments. Key insights include the efficacy of dual antithrombotic therapy over triple therapy, the benefits of anticoagulation alone post-left atrial appendage occlusion, and the superior cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists in diabetes management.

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-way Comparison from AUGUSTUS Aug 26, 2024

Dr. Valentin Fuster discusses the Augustus trial’s groundbreaking findings on antithrombotic strategies for atrial fibrillation patients post-acute coronary syndrome or PCI. The study reveals that a regimen of apixaban and a P2Y12 inhibitor—without aspirin—offers superior safety and efficacy, challenging traditional triple therapy approaches.

Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Watchman FLX Left Atrial Appendage Occlusion Aug 26, 2024

In the September 3, 2024, issue of JACC, Dr. Samuel Reinhart and team find that using direct oral anticoagulants alone is associated with fewer adverse events compared to combining them with aspirin after left atrial appendage occlusion. Their large-scale study suggests this streamlined approach might be optimal, though further randomized trials are needed to address limitations and refine long-term antithrombotic strategies.

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM Aug 26, 2024

In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.

Continuous Rhythm Monitoring with Implanted Loop Recorders in Children and Adolescents with Brugada Syndrome Aug 26, 2024

In the September 3, 2024, issue of JACC, Dr. Valentin Fuster introduces a pivotal study on Brugada syndrome in children and adolescents. This research, led by Dr. Marco Berganti and colleagues, demonstrates how continuous monitoring with implanted loop recorders provides critical insights into arrhythmias and syncope in young patients, highlighting the potential for future AI-driven personalized care in this complex condition.

Antithrombotic Strategies for Patients with Peripheral Artery Disease: JACC Scientific Statement Aug 26, 2024

In the September 3rd, 2024 issue of JACC, a new scientific statement delves into antithrombotic strategies for peripheral artery disease (PAD), highlighting the challenges and advancements in treatment. The review emphasizes that while traditional therapies like aspirin and clopidogrel remain crucial, combining aspirin with low-dose rivaroxaban offers a promising approach for reducing major adverse events and limb outcomes, despite an increased bleeding risk.

JACC - August 27, 2024 Issue Summary Aug 19, 2024

In this episode, Dr. Valentin Fuster covers four original papers focusing on cardiovascular disease. Highlights include the effectiveness of semaglutide in reducing weight and improving heart failure symptoms, long-lasting effects of OPASAN on lipoprotein(a) levels, the impact of low-dose rivaroxaban plus aspirin on fragile patients post-revascularization, and the promising use of AI-based ECG for predicting biventricular dysfunction in congenital heart disease.

Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials Aug 19, 2024

Dr. Valentin Fuster discusses a study on the efficacy of semaglutide for treating obesity-related heart failure with preserved ejection fraction, highlighting that the drug significantly reduced body weight and improved heart failure symptoms in both men and women. Notably, women experienced greater weight loss than men, but this did not translate into better improvement in heart failure-related symptoms, underscoring complex sex-related differences in cardiovascular health.

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results Aug 19, 2024

In this episode, Dr. Valentin Fuster explores findings from the Phase 2 OCEAN-LDO trial assessing the off-treatment effects of the RNA-based drug alpcisiran on lipoprotein(a) [Lp(a)] levels. The study found that high doses of alpcisiran reduced Lp(a) levels by up to 95% during treatment, with a sustained reduction of 27-76% persisting up to 96 weeks after discontinuation, and no new safety concerns emerged.

Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization Aug 19, 2024

Dr. Valentin Fuster discusses a study on the effects of low-dose rivaroxaban combined with aspirin in fragile patients after lower extremity revascularization, focusing on the balance between efficacy and safety. It highlights that while frailty increases the risk of adverse outcomes, rivaroxaban reduces ischemic events but also raises bleeding risks, regardless of frailty status. The editorial emphasizes that frailty should not preclude the use of combined antithrombotic therapy, advocating for personalized treatment approaches.

Deep Learning-Based Electrocardiogram Analysis Predicts Biventricular Dysfunction and Dilation in Congenital Heart Disease Aug 19, 2024

Dr. Valentin Fuster evaluates a deep learning model designed to predict left and right ventricular dysfunction and dilation in congenital heart disease patients using ECG and CMR data. The research demonstrated that AI ECG can reliably identify significant cardiovascular issues, though future work should focus on refining thresholds and validating the model across diverse populations and healthcare settings.

Structural Cardiac Interventions in Patients with Heart Failure: JACC Scientific Statement Aug 19, 2024

In this episode, Dr. Valentin Fuster provides an overview of a scientific statement on structural cardiac interventions in heart failure. It details advances in percutaneous therapies for ventricular reshaping, valvular heart disease interventions, and tricuspid valve issues, while also highlighting gaps in current treatments and areas for future research.

Treatment of Transcatheter Aortic Valve Thrombosis: JACC Review Topic of the Week Aug 19, 2024

Dr. Valentin Fuster discusses the treatment and diagnosis of transcatheter aortic valve thrombosis, focusing on its manifestations, diagnostic techniques using multi-slice computed tomography, and a proposed treatment algorithm. It highlights the difference between subclinical and clinical thrombosis and provides a detailed approach to managing both, including antiplatelet and anticoagulant therapies.

JACC - August 20, 2024 Issue Summary Aug 12, 2024

Audio Summary of the August 20 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Prescription Patterns for Sodium Glucose Cotransporter-2 Inhibitors in US Health Systems Aug 12, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes Aug 12, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR: Results of a Patient-Level Pooled Analysis Aug 12, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay Aug 12, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions Aug 12, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - August 13, 2024 Issue Summary Aug 05, 2024

Audio Summary of the August 13 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Real-world 1-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study Aug 05, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Contemporary Pediatric Heart Transplant Waitlist Mortality Aug 05, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients with Valvular Heart Disease Aug 05, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Myocardial Strain Measured by Magnetic Resonance Imaging Predicts Cardiovascular Morbidity and Death Aug 05, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Ending trans fat-the first-ever global elimination program for a noncommunicable disease risk factor: JACC International Aug 05, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - August 6, 2024 Issue Summary Jul 29, 2024

Audio Summary of the August 6 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood Jul 29, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

The influence of epicardial resistance on microvascular resistance reserve Jul 29, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

A Patch Wearable Cardioverter Defibrillator for Patients at Risk of Sudden Cardiac Arrest Jul 29, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients with Type 2 Diabetes Jul 29, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review Jul 29, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - July 30, 2024 Issue Summary Jul 22, 2024

Audio Summary of the July 30 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Association of Adverse Clinical Outcomes with Peri-Infarct Ischemia Detected by Stress Cardiac Magnetic Imaging Jul 22, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Lipidomic Risk Score to Enhance Cardiovascular Risk Stratification for Primary Prevention Jul 22, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Temperature and Neurologic Outcomes in Neonates Undergoing Cardiac Surgery: A Society of Thoracic Surgeons Study Jul 22, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Mortality after Procedural or Spontaneous Myocardial Infarction Jul 22, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Treating Depression to Improve Survival in Coronary Heart Disease: What Have We Learned? Jul 22, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - July 23, 2024 Issue Summary Jul 15, 2024

Audio Summary of the July 23 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Effects of Rapid Up-Titration of Neurohormonal Blockade in Patients with Acute Decompensated Heart Failure Jul 15, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Impact of Anatomical and Viability-guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy Jul 15, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Apixaban versus Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights from ARTESiA Jul 15, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy Jul 15, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Sutureless Valves, a “Wireless” Option for Patients with Aortic Valve Disease: JACC State-of-the-Art Review Jul 15, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - July 16, 2024 Issue Summary Jul 08, 2024

Audio Summary of the July 16 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial Jul 08, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Semaglutide and NYHA Class in Obesity-Related Heart Failure with Preserved Ejection Fraction: the STEP-HFpEF Program Jul 08, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Glycemic Control and Coronary Stent Failure in Patients with Type 2 Diabetes Mellitus Jul 08, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Percutaneous coronary revascularization strategies after myocardial infarction: a systematic review and network meta-analysis Jul 08, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

The Role of Psychosocial Stress on Cardiovascular disease in Women: JACC-State-of-the-Art-Review Jul 08, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - July 9, 2024 Issue Summary Jul 01, 2024

Audio Summary of the July 9 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients with Diabetic Cardiomyopathy Jul 01, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs Jul 01, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Impact of Lp(a) Level on LDL-Cholesterol or Apolipoprotein B-Related Risk of Coronary Heart Disease Jul 01, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Coronary artery bypass graft failure in women: incidence and clinical implications Jul 01, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Tricuspid Regurgitation in Patients with Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review Jul 01, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - July 2, 2024 Issue Summary Jun 24, 2024

Audio Summary of the July 2 issue of JACC, by Dr. Valentin Fuster, Emeritus Editor in Chief

Symptoms as a predictor of the placebo-controlled efficacy of PCI in stable coronary artery disease Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Prognostic Value of a 6-Minute Walk Test in Patients with Cardiac Transthyretin Amyloidosis Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Lessons for Cardiovascular Clinical Investigators: the Tumultuous 2500-Year Journey of Physicians Who Ignited Our Fire Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Transforming Cardiovascular Care with Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review Jun 24, 2024

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

JACC - June 25, 2024 Issue Summary Jun 17, 2024

Audio Summary of the June 25 issue of JACC, by Dr. Valentin Fuster

Ten-Year Mortality after ST-Segment Elevation Myocardial Infarction Compared to the General Population Jun 17, 2024

Commentary by Dr. Valentin Fuster

Timing of P2Y12-inhibitor Administration in Patients with STEMI Undergoing Primary PCI Jun 17, 2024

Commentary by Dr. Valentin Fuster

Association of Autoimmune Diseases with Coronary Atherosclerosis Severity and Ischemic Events Jun 17, 2024

Commentary by Dr. Valentin Fuster

Randomized Trial of a Vascular Care Team vs Education for Patients with Peripheral Artery Disease Jun 17, 2024

Commentary by Dr. Valentin Fuster

Intravenous Iron Repletion for Patients with Heart Failure and Iron Deficiency: JACC State-of-the-Art Review Jun 17, 2024

Commentary by Dr. Valentin Fuster

Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review Jun 17, 2024

Commentary by Dr. Valentin Fuster

JACC - June 18, 2024 Issue Summary Jun 10, 2024

Audio Summary of the June 18 issue of JACC, by Dr. Valentin Fuster

SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy Jun 10, 2024

Commentary by Dr. Valentin Fuster

Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Impaired Renal Function Jun 10, 2024

Commentary by Dr. Valentin Fuster

Impact of Social Determinants of Health on Predictive Models for Outcomes after Congenital Heart Surgery Jun 10, 2024

Commentary by Dr. Valentin Fuster

Geographical Mapping of Gender Disparities in Authorship of Cardiovascular Literature Jun 10, 2024

Commentary by Dr. Valentin Fuster

2024 ACC/AHA/AACVPR/APMA/ ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Jun 10, 2024

Commentary by Dr. Valentin Fuster

Artificial Intelligence for Cardiovascular Care — Part 1: Advances : JACC Review Topic of the Week Jun 10, 2024

Commentary by Dr. Valentin Fuster

Artificial Intelligence in Cardiovascular Care — Part 2: Applications: JACC Review Topic of the Week Jun 10, 2024

Commentary by Dr. Valentin Fuster

JACC - June 11, 2024 Issue Summary Jun 03, 2024

Audio Summary of the June 11 issue of JACC, by Dr. Valentin Fuster

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction Jun 03, 2024

Commentary by Dr. Valentin Fuster

Randomized Trial of Remote Assessment of Patients after an Acute Coronary Syndrome Jun 03, 2024

Commentary by Dr. Valentin Fuster

Excess Apolipoprotein B and Cardiovascular Risk in Women and Men Jun 03, 2024

Commentary by Dr. Valentin Fuster

Global, and Regional Cardiovascular Mortality Attributable to Non-optimal Temperatures over Time Jun 03, 2024

Commentary by Dr. Valentin Fuster

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines Jun 03, 2024

Commentary by Dr. Valentin Fuster

Pollution and Cardiovascular Disease, Part 2: Water, Soil, Noise and Light Pollution: JACC Focus Seminar Jun 03, 2024

Commentary by Dr. Valentin Fuster

Pollution and Cardiovascular Disease, Part 1: Environmentally Not So Friendly:Global Warming, Air Pollution,and Wildfires: JACC Focus Seminar Jun 03, 2024

Commentary by Dr. Valentin Fuster

JACC - June 4, 2024 Issue Summary May 26, 2024

Audio Summary of the June 4 issue of JACC, by Dr. Valentin Fuster

Coronary Atherosclerotic Plaque Activity and Myocardial Infarction: A vessel-level analysis of the PRE18FFIR study May 26, 2024

Commentary by Dr. Valentin Fuster

Effects of Sacubitril/Valsartan in Patients with Heart Failure Across the Spectrum of Kidney Risk May 26, 2024

Commentary by Dr. Valentin Fuster

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI May 26, 2024

Commentary by Dr. Valentin Fuster

Transcatheter Covered Stent Exclusion of Superior Sinus Venosus Defects May 26, 2024

Commentary by Dr. Valentin Fuster

Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review May 26, 2024

Commentary by Dr. Valentin Fuster

Reperfusion Injury in Patients with Acute Myocardial Infarction: JACC: Scientific Statement May 26, 2024

Commentary by Dr. Valentin Fuster

JACC - May 28, 2024 Issue Summary May 20, 2024

Audio Summary of the May 28 issue of JACC, by Dr. Valentin Fuster

Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Nonobstructive Hypertrophic Cardiomyopathy: Phase 2 Study May 20, 2024

Commentary by Dr. Valentin Fuster

Clinical Outcome of Different Microvascular Injury Patterns after STEMI - A Multicenter Cardiac MRI Study May 20, 2024

Commentary by Dr. Valentin Fuster

Prognostic Value of MRR After Primary PCI: a Pooled Analysis of Individual Patient Data May 20, 2024

Commentary by Dr. Valentin Fuster

A Technology-Assisted Web Application for Consumer Access to a Non-prescription Statin Medication May 20, 2024

Commentary by Dr. Valentin Fuster

Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review May 20, 2024

Commentary by Dr. Valentin Fuster

Clinical Risk Assessment Across the Lifespan in Patients with Congenital Heart Disease: JACC Scientific Statement May 20, 2024

Commentary by Dr. Valentin Fuster

JACC - May 21, 2024 Issue Summary May 13, 2024

Audio Summary of the May 21 issue of JACC, by Dr. Valentin Fuster

An Inclisiran First Strategy vs Usual Care in Patients with Atherosclerotic Cardiovascular Disease May 13, 2024

Commentary by Dr. Valentin Fuster

Small Left Ventricle is Associated with an Increased Cardiovascular Risk in Patients with Atrial Fibrillation May 13, 2024

Commentary by Dr. Valentin Fuster

Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial May 13, 2024

Commentary by Dr. Valentin Fuster

Case Volumes and Outcomes among Early Career Interventional Cardiologists in the United States May 13, 2024

Commentary by Dr. Valentin Fuster

Managing Implanted Cardiac Electronic Devices in Patients with Severe Tricuspid Regurgitation: JACC State-of-the-Art Review May 13, 2024

Commentary by Dr. Valentin Fuster

Targeting the Substrate for Atrial Fibrillation: JACC Review Topic of the Week May 13, 2024

Commentary by Dr. Valentin Fuster

JACC - May 14, 2024 Issue Summary May 06, 2024

Audio Summary of the May 14 issue of JACC, by Dr. Valentin Fuster

Prevalence of Cardiovascular Disease and Risk Factors among National Football League Alumni and Family Members May 06, 2024

Commentary by Dr. Valentin Fuster

Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Cardiomyopathies May 06, 2024

Commentary by Dr. Valentin Fuster

Uniform or Sex-Specific Cardiac Troponin Thresholds to Rule Out Myocardial Infarction at Presentation May 06, 2024

Commentary by Dr. Valentin Fuster

Long-term Cardiovascular Risk Associated with Treatment of Attention-Deficit/Hyperactivity Disorder in Adults May 06, 2024

Commentary by Dr. Valentin Fuster

Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5 May 06, 2024

Commentary by Dr. Valentin Fuster

JACC - May 7, 2024 Issue Summary Apr 29, 2024

Audio Summary of the May 7 issue of JACC, by Dr. Valentin Fuster

Combined effects of clonal hematopoiesis and degree of carotid stenosis on cardiovascular mortality Apr 29, 2024

Commentary by Dr. Valentin Fuster

Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction Apr 29, 2024

Commentary by Dr. Valentin Fuster

Association of Lipoprotein(a) Levels with Myocardial Infarction in Patients with Low Attenuation Plaque Apr 29, 2024

Commentary by Dr. Valentin Fuster

Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients with Obstructive Sleep Apnea Apr 29, 2024

Commentary by Dr. Valentin Fuster

JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction Apr 29, 2024

Commentary by Dr. Valentin Fuster

JACC - April 30, 2024 Issue Summary Apr 22, 2024

Audio Summary of the April 30 issue of JACC, by Dr. Valentin Fuster

Limb Outcomes with Ticagrelor Plus Aspirin in Patients with Diabetes Mellitus and Atherosclerosis Apr 22, 2024

Commentary by Dr. Valentin Fuster

Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives Apr 22, 2024

Commentary by Dr. Valentin Fuster

Permanent Pacemaker Implantation and Long-term Outcomes of Patients Undergoing Concomitant Mitral and Tricuspid Valve Surgery Apr 22, 2024

Commentary by Dr. Valentin Fuster

Association of Disrupted Delta Wave Activity During Sleep with Long-Term Cardiovascular Disease and Mortality Apr 22, 2024

Commentary by Dr. Valentin Fuster

Malignant Hypertension – A Systemic Cardiovascular Disease: JACC Review Topic of the Week Apr 22, 2024

Commentary by Dr. Valentin Fuster

JACC - April 16, 2024 Issue Summary Apr 08, 2024

Audio Summary of the April 16 issue of JACC, by Dr. Valentin Fuster

Variation in Health Status with Invasive vs Conservative Management of Chronic Coronary Disease Apr 08, 2024

Commentary by Dr. Valentin Fuster

Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score Apr 08, 2024

Commentary by Dr. Valentin Fuster

Water Conservation Overrides Osmotic Diuresis during SGLT2 Inhibition in Patients with Heart Failure Apr 08, 2024

Commentary by Dr. Valentin Fuster

Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults with Congenital Heart Disease Apr 08, 2024

Commentary by Dr. Valentin Fuster

2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction Apr 08, 2024

Commentary by Dr. Valentin Fuster

The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar Apr 08, 2024

Commentary by Dr. Valentin Fuster

JACC - April 9, 2024 Issue Summary Apr 01, 2024

Audio Summary of the April 9 issue of JACC, by Dr. Valentin Fuster

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction Apr 01, 2024

Commentary by Dr. Valentin Fuster

Stratifying Disease Progression in Patients with Cardiac ATTR Amyloidosis Apr 01, 2024

Commentary by Dr. Valentin Fuster

Efficacy and Safety of Dapagliflozin in Patients with Acute Heart Failure Apr 01, 2024

Commentary by Dr. Valentin Fuster

Early Outcomes from a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry Apr 01, 2024

Commentary by Dr. Valentin Fuster

Today’s Infective Endocarditis: Not What You Learned in Medical School Apr 01, 2024

Commentary by Dr. Valentin Fuster

JACC - April 2, 2024 Issue Summary Mar 25, 2024

Audio Summary of the April 2 issue of JACC, by Dr. Valentin Fuster

Validation of the ACC Expert Consensus Decision Pathway for Patients with Chest Pain Mar 25, 2024

Commentary by Dr. Valentin Fuster

Risk of Dementia During Antihypertensive Drug Therapy in the Elderly Mar 25, 2024

Commentary by Dr. Valentin Fuster

Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease Mar 25, 2024

Commentary by Dr. Valentin Fuster

Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients with Cyanotic Congenital Heart Disease Mar 25, 2024

Commentary by Dr. Valentin Fuster

JACC - March 26, 2024 Issue Summary Mar 18, 2024

Audio Summary of the March 26 issue of JACC, by Dr. Valentin Fuster

Prevalence and Outcomes of Patients With Discordant High-Gradient Aortic Stenosis Mar 18, 2024

Commentary by Dr. Valentin Fuster

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure Mar 18, 2024

Commentary by Dr. Valentin Fuster

Coarctation of Aorta With Tricuspid Aortic Valve Is Not Associated With Ascending Aortic Aneurysm Mar 18, 2024

Commentary by Dr. Valentin Fuster

Frailty and Cognitive Function in Middle-Aged and Older Adults With Congenital Heart Disease Mar 18, 2024

Commentary by Dr. Valentin Fuster

Genetic Factors Altering Immune Responses in Atrial Fibrillation: JACC Review Topic of the Week Mar 18, 2024

Commentary by Dr. Valentin Fuster

JACC - March 19, 2024 Issue Summary Mar 11, 2024

Audio Summary of the March 19 issue of JACC, by Dr. Valentin Fuster

Association of Antiarrhythmic Drug Therapy with Syncope and Pacemaker Implantation in Patients with Atrial Fibrillation Mar 11, 2024

Commentary by Dr. Valentin Fuster

Electrophysiological Characterization of Subclinical and Overt Hypertrophic Cardiomyopathy by Magnetic Resonance Imaging-Guided Electrocardiography Mar 11, 2024

Commentary by Dr. Valentin Fuster

Kidney Injury After Minimal Radiographic Contrast Administration in Patients with Acute Coronary Syndromes Mar 11, 2024

Commentary by Dr. Valentin Fuster

Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease Mar 11, 2024

Commentary by Dr. Valentin Fuster

Histological Typing in Patients with Cardiac Amyloidosis: JACC Review Topic of the Week Mar 11, 2024

Commentary by Dr. Valentin Fuster

JACC - March 12, 2024 Issue Summary: Dr. Valentin Fuster's Top Picks for 2023 Mar 04, 2024

Audio Summary of the March 12 special issue of JACC, by Dr. Valentin Fuster

JACC - March 5, 2024 Issue Summary Feb 26, 2024

Audio Summary of the March 5 issue of JACC, by Dr. Valentin Fuster

Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease Feb 26, 2024

Commentary by Dr. Valentin Fuster

Surveillance Stress Testing After Percutaneous Intervention for Patients With Multivessel or Left Main Coronary Disease Feb 26, 2024

Commentary by Dr. Valentin Fuster

Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI Feb 26, 2024

Commentary by Dr. Valentin Fuster

Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting Feb 26, 2024

Commentary by Dr. Valentin Fuster

Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review Feb 26, 2024

Commentary by Dr. Valentin Fuster

JACC - February 27, 2024 Issue Summary Feb 19, 2024

Audio Summary of the February 27 issue of JACC, by Dr. Valentin Fuster

" Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality" Feb 19, 2024

Commentary by Dr. Valentin Fuster

Phenotypic Expression and Clinical Outcomes in Patients with Arrhythmogenic Cardiomyopathies Feb 19, 2024

Commentary by Dr. Valentin Fuster

Infective Endocarditis in Patients Addicted to Injected Opioid Drugs Feb 19, 2024

Commentary by Dr. Valentin Fuster

Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer Feb 19, 2024

Commentary by Dr. Valentin Fuster

“Food Is Medicine” Strategies for Nutrition Security and Cardiometabolic Health Equity: JACC State-of-the-Art Review Feb 19, 2024

Commentary by Dr. Valentin Fuster

JACC - February 20, 2024 Issue Summary Feb 12, 2024

Audio Summary of the February 20 issue of JACC, by Dr. Valentin Fuster

Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults Feb 12, 2024

Commentary by Dr. Valentin Fuster

Intrahepatic Transcriptomics Differentiate Advanced Fibrosis And Clinical Outcomes In Adults With Fontan Circulation Feb 12, 2024

Commentary by Dr. Valentin Fuster

Increased Risk of Myocardial Infarction, Heart Failure And Atrial Fibrillation After Spinal Cord Injury Feb 12, 2024

Commentary by Dr. Valentin Fuster

Vascular Regenerative Cell Deficiencies In South Asian Adults Feb 12, 2024

Commentary by Dr. Valentin Fuster

Participation In Competitive Sports By Patients With Congenital Heart Disease: Aha/Acc And Eapc/Esc/Aepc Guidelines Comparison Feb 12, 2024

Commentary by Dr. Valentin Fuster

JACC - February 13, 2024 Issue Summary Feb 05, 2024

Audio Summary of the February 13 issue of JACC, by Dr. Valentin Fuster

Randomized Trial of Effect of Bariatric Surgery On Blood Pressure After Five Years Feb 05, 2024

Commentary by Dr. Valentin Fuster

Long-Term Efficacy of Evolocumab In Patients With Or Without Multivessel Coronary Disease Feb 05, 2024

Commentary by Dr. Valentin Fuster

Bleeding Outcomes In Patients Treated With Asundexian In Phase Ii Trials Feb 05, 2024

Commentary by Dr. Valentin Fuster

Implantable Hemodynamic Monitors Improve Survival In Patients With Heart Failure And Reduced Ejection Fraction Feb 05, 2024

Commentary by Dr. Valentin Fuster

Measuring Coronary Blood Flow And Microvascular Resistance By Thermodilution: JACC Review Topic of the Week Feb 05, 2024

Commentary by Dr. Valentin Fuster

JACC - February 6, 2024 Issue Summary Jan 29, 2024

Audio Summary of the February 6 issue of JACC, by Dr. Valentin Fuster

Outcomes According To Coronary Revascularization Modality In the Ischemia Trial Jan 29, 2024

Commentary by Dr. Valentin Fuster

Universal Risk Prediction For Individuals With And Without Atherosclerotic Cardiovascular Disease Jan 29, 2024

Commentary by Dr. Valentin Fuster

Large-Scale Proteomics Identifies Novel Biomarkers And Circulating Risk Factors For Aortic Stenosis Jan 29, 2024

Commentary by Dr. Valentin Fuster

Clinical Presentation, Classification, And Outcomes of Cardiogenic Shock In Children Jan 29, 2024

Commentary by Dr. Valentin Fuster

JACC - January 30, 2024 Issue Summary Jan 22, 2024

Audio Summary of the January 30 issue of JACC, by Dr. Valentin Fuster

Randomized Trial of Macitentan/Tadalafil Combination Therapy For Pulmonary Artery Hypertension Jan 22, 2024

Commentary by Dr. Valentin Fuster

Transcatheter Edge-To-Edge Repair In Coapt-Ineligible Patients With Functional Mitral Regurgitation Jan 22, 2024

Commentary by Dr. Valentin Fuster

Prognostic Implications of Initial Focal Contrast Enhancement In Acute Type B Intramural Hematoma Jan 22, 2024

Commentary by Dr. Valentin Fuster

Growth of the Neo-Aortic Root And Prognosis of Transposition of the Great Arteries Jan 22, 2024

Commentary by Dr. Valentin Fuster

Racial And Ethnic Disparities In Perioperative Health Care Among Patients Undergoing Cardiac Surgery: JACC State-of-the-Art Review Jan 22, 2024

Commentary by Dr. Valentin Fuster

JACC - January 23, 2024 Issue Summary Jan 15, 2024

Audio Summary of the January 23 issue of JACC, by Dr. Valentin Fuster

Lipoprotein(A) is Markedly More Atherogenic Than Ldl: An Apolipoprotein B-Based Genetic Analysis Jan 15, 2024

Commentary by Dr. Valentin Fuster

Guiding Intervention For Complex Coronary Lesions By Optical Coherence Tomography Or Intravascular Ultrasound Jan 15, 2024

Commentary by Dr. Valentin Fuster

Risk of Death In Patients With Coronary Artery Disease Taking Nitrates And Phosphodiesterase-5-Inhibitors Jan 15, 2024

Commentary by Dr. Valentin Fuster

Anxiety And Depression Symptoms In An International Study of Adults With Congenital Heart Disease Jan 15, 2024

Commentary by Dr. Valentin Fuster

When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review Jan 15, 2024

Commentary by Dr. Valentin Fuster

JACC - January 16, 2024 Issue Summary Jan 08, 2024

Audio Summary of the January 16 issue of JACC, by Dr. Valentin Fuster

Rethinking False Positive Exercise Electrocardiographic Stress Tests By Assessing Coronary Microvascular Function Jan 08, 2024

Commentary by Dr. Valentin Fuster

Sex-Specific Prognosis of Left Ventricular Size And Function Following Repair of Degenerative Mitral Regurgitation Jan 08, 2024

Commentary by Dr. Valentin Fuster

Cardiac Reoperation Or Transcatheter Mitral Valve Replacement For Patients With Failed Mitral Prostheses Jan 08, 2024

Commentary by Dr. Valentin Fuster

Comparison of Direct Oral Anticoagulants Vs Vitamin-K Antagonists After Transcatheter Mitral Valve Replacement Jan 08, 2024

Commentary by Dr. Valentin Fuster

Sudden Cardiac Death In Young Athletes: Jacc State-Of-The-Art Review Jan 08, 2024

Commentary by Dr. Valentin Fuster

JACC - January 2 - 9, 2024 Issue Summary Jan 02, 2024

Audio Summary of the January 2 - 9 issue of JACC, by Dr. Valentin Fuster

Health Status After Transcatheter Tricuspid-Valve Repair In Patients With Severe Tricuspid Regurgitation: Triluminate Pivotal Trial Jan 02, 2024

Commentary by Dr. Valentin Fuster

Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After Pci: Stopdapt-2 5-Year Results Jan 02, 2024

Commentary by Dr. Valentin Fuster

Contemporary Management And Outcomes of Patients With High-Risk Pulmonary Embolism Jan 02, 2024

Commentary by Dr. Valentin Fuster

Lung-To-Heart Nano-In-Micro Peptide Promotes Cardiac Recovery In a Pig Model of Chronic Heart Failure Jan 02, 2024

Commentary by Dr. Valentin Fuster

Antithrombotic Therapy For Patients Undergoing Cardiac Electrophysiological And Interventional Procedures: Jacc State-Of-The-Art Review Jan 02, 2024

Commentary by Dr. Valentin Fuster

2023 Acc/Aha/Accp/Hrs Guideline For the Diagnosis And Management of Atrial Fibrillation Jan 02, 2024

Commentary by Dr. Valentin Fuster

JACC - December 19 - 26, 2023 Issue Summary: A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action Dec 11, 2023

Audio Summary of the December 19 - 26 issue of JACC, by Dr. Valentin Fuster

JACC - December 12, 2023 Issue Summary Dec 04, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in Seven Clinical Trials Dec 04, 2023

Commentary by Dr. Valentin Fuster

Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events Dec 04, 2023

Commentary by Dr. Valentin Fuster

Association of Lipoprotein(a) Levels with Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis Dec 04, 2023

Commentary by Dr. Valentin Fuster

Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease Dec 04, 2023

Commentary by Dr. Valentin Fuster

Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement Dec 04, 2023

Commentary by Dr. Valentin Fuster

JACC - December 5, 2023 Issue Summary Nov 27, 2023

Audio Summary of the Dec 5 issue of JACC, by Dr. Valentin Fuster

Longitudinal Changes in Pulmonary Pressure in Late Life: The Atherosclerosis Risk in Communities (ARIC) Study Nov 27, 2023

Commentary by Dr. Valentin Fuster

Systemic Atrioventricular Valve Surgery in Patients with Congenitally Corrected Transposition of the Great Vessels Nov 27, 2023

Commentary by Dr. Valentin Fuster

Adjusting for Congenital Heart Surgery Risk Using Administrative Data Nov 27, 2023

Commentary by Dr. Valentin Fuster

Neuroimaging and neurodevelopmental outcomes among individuals with complex congenital heart disease Nov 27, 2023

Commentary by Dr. Valentin Fuster

Comparison of Intravascular Imaging, Functional or Angiographically Guided Coronary Intervention Nov 27, 2023

Commentary by Dr. Valentin Fuster

JACC - November 28, 2023 Issue Summary Nov 20, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Determinants of Progression And Regression of Subclinical Atherosclerosis Over Six Years Nov 20, 2023

Commentary by Dr. Valentin Fuster

Primary Prevention of Subclinical Atherosclerosis In Young Adults: Jacc Review Topic of the Week Nov 20, 2023

Commentary by Dr. Valentin Fuster

Semaglutide Effects According to Ejection Fraction in Heart Failure with Preserved Ejection Fraction and Obesity Nov 20, 2023

Commentary by Dr. Valentin Fuster

The Mortality Burden of Untreated Aortic Stenosis Nov 20, 2023

Commentary by Dr. Valentin Fuster

Can Machine Learning Aid the Selection of Percutaneous vs. Surgical Revascularisation? Nov 20, 2023

Commentary by Dr. Valentin Fuster

Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement Nov 20, 2023

Commentary by Dr. Valentin Fuster

JACC - November 21, 2023 Issue Summary Nov 13, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation Nov 13, 2023

Commentary by Dr. Valentin Fuster

Sleep-Related Hypoxia, Right Ventricular Dysfunction and Survival in Group 1 Pulmonary Arterial Hypertension: PVDOMICS Study Nov 13, 2023

Commentary by Dr. Valentin Fuster

Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry Nov 13, 2023

Commentary by Dr. Valentin Fuster

Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients with Non-ST-Elevation Acute Coronary Syndromes Nov 13, 2023

Commentary by Dr. Valentin Fuster

Management of Adults with Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review Nov 13, 2023

Commentary by Dr. Valentin Fuster

JACC - November 14, 2023 Issue Summary Nov 06, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Association of Age and Sex with Use of Transcatheter Aortic Valve Replacement in France Nov 06, 2023

Commentary by Dr. Valentin Fuster

Multi-omics analysis provides novel pathways related to progression of heart failure Nov 06, 2023

Commentary by Dr. Valentin Fuster

Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease Nov 06, 2023

Commentary by Dr. Valentin Fuster

Deep Learning-Enabled Assessment of Left Heart Structure and Function Predicts Cardiovascular Outcomes Nov 06, 2023

Commentary by Dr. Valentin Fuster

JACC - November 7, 2023 Issue Summary Oct 30, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications Oct 30, 2023

Commentary by Dr. Valentin Fuster

Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease Oct 30, 2023

Commentary by Dr. Valentin Fuster

Efficacy of Sotagliflozin in Adults with Type 2 Diabetes In Relation to Baseline Hemoglobin A1c Oct 30, 2023

Commentary by Dr. Valentin Fuster

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function Oct 30, 2023

Commentary by Dr. Valentin Fuster

Implementation of Global Hearts Hypertension Control Programs in 32 Low- and Middle-Income Countries: JACC International Oct 30, 2023

Commentary by Dr. Valentin Fuster

JACC - October 31, 2023 Issue Summary Oct 23, 2023

Audio Summary of the October 31 issue of JACC, by Dr. Valentin Fuster

Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy Oct 23, 2023

Commentary by Dr. Valentin Fuster

Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives Oct 23, 2023

Commentary by Dr. Valentin Fuster

Network Meta-analysis of Initial Antithrombotic Regimens after Left Atrial Appendage Occlusion Oct 23, 2023

Commentary by Dr. Valentin Fuster

Public Out-of-hospital Cardiac Arrests in Residential Neighborhoods Oct 23, 2023

Commentary by Dr. Valentin Fuster

Cardiovascular Fellowship Training in Cardio-Obstetrics: JACC Review Topic of the Week Oct 23, 2023

Commentary by Dr. Valentin Fuster

JACC - October 24, 2023 Issue Summary Oct 16, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Psychosocial Characteristics of Women Presenting with Myocardial Infarction With or Without Obstructive Coronary Arteries Oct 16, 2023

Commentary by Dr. Valentin Fuster

Impact of Positron Emission Tomographic Myocardial Perfusion Imaging on Patient Selection for Revascularization Oct 16, 2023

Commentary by Dr. Valentin Fuster

Coronary Fractional Flow Reserve Assessment by Computerized Tomography in Patients with Type 2 Myocardial Infarction Oct 16, 2023

Commentary by Dr. Valentin Fuster

Risk-Stratification for Hospital Mortality and Postoperative Complications in Patients with Shock undergoing Cardiac Surgery Oct 16, 2023

Commentary by Dr. Valentin Fuster

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints Oct 16, 2023

Commentary by Dr. Valentin Fuster

JACC - October 17, 2023 Issue Summary Oct 09, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Comparison of Antiplatelet Monotherapies after Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks Oct 09, 2023

Commentary by Dr. Valentin Fuster

10-year Cardiovascular Risk in Patients with Newly-Diagnosed Type 2 Diabetes Mellitus Oct 09, 2023

Commentary by Dr. Valentin Fuster

Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients with Suspected Coronary Artery Disease Oct 09, 2023

Commentary by Dr. Valentin Fuster

Magnetic Resonance Spectroscopy of Brain Metabolism in Fetuses with Congenital Heart Disease Oct 09, 2023

Commentary by Dr. Valentin Fuster

International Consensus on Differential Diagnosis and Management of Patients with Danon Disease: JACC State-of-the-Art Review Oct 09, 2023

Commentary by Dr. Valentin Fuster

JACC - October 10, 2023 Issue Summary Oct 02, 2023

Audio Summary of the October 10 issue of JACC, by Dr. Valentin Fuster.

Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events Oct 02, 2023

Commentary by Dr. Valentin Fuster

Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice Oct 02, 2023

Commentary by Dr. Valentin Fuster

Outcomes of Heart Transplant Donation after Circulatory Death Oct 02, 2023

Commentary by Dr. Valentin Fuster

Prognostic Implications of the Extent of Cardiac Damage in Patients with Fabry Disease Oct 02, 2023

Commentary by Dr. Valentin Fuster

Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review Oct 02, 2023

Commentary by Dr. Valentin Fuster

Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week Oct 02, 2023

Commentary by Dr. Valentin Fuster

JACC - October 3, 2023 Issue Summary Sep 25, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals Sep 25, 2023

Commentary by Dr. Valentin Fuster

Validation of Risk-Stratification for Cardiac Events in Pregnant Women with Valvular Heart Disease Sep 25, 2023

Commentary by Dr. Valentin Fuster

Genetic Insights on the Relation of Vascular Risk Factors and Cervical Artery Dissection Sep 25, 2023

Commentary by Dr. Valentin Fuster

Outcomes after Hybrid Palliation for Infants with Critical Left Heart Obstruction Sep 25, 2023

Commentary by Dr. Valentin Fuster

Durable Mechanical Circulatory Support: JACC Scientific Statement Sep 25, 2023

Commentary by Dr. Valentin Fuster

JACC - September 26, 2023 Issue Summary Sep 18, 2023

Audio Summary of the September 26 issue of JACC, by Dr. Valentin Fuster

Transcatheter Edge-to-Edge Repair in 5,000 Patients with Secondary Mitral Regurgitation: COAPT Post-Approval Study Sep 18, 2023

Commentary by Dr. Valentin Fuster

Association of High-Sensitivity Cardiac Troponin-T with 30-day and Five-year Mortality after Cardiac Surgery Sep 18, 2023

Commentary by Dr. Valentin Fuster

Impaired Renal Function and Major Cardiovascular Events in Young Adults Sep 18, 2023

Commentary by Dr. Valentin Fuster

Chronic Medication Burden after Cardiac Surgery for Pediatric Medicaid Beneficiaries Sep 18, 2023

Commentary by Dr. Valentin Fuster

Clinical Pathway for Coronary Atherosclerosis in Patients without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review Sep 18, 2023

Commentary by Dr. Valentin Fuster

JACC - September 19, 2023 Issue Summary Sep 11, 2023

Audio Summary of the September 19 issue of JACC, by Dr. Valentin Fuster

Impact of Complete Revascularization in the ISCHEMIA Trial Sep 11, 2023

Commentary by Dr. Valentin Fuster

Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging with Cardiovascular Outcomes Sep 11, 2023

Commentary by Dr. Valentin Fuster

20-Year Experience with Repair of Pulmonary Atresia or Stenosis and Major Aortopulmonary Collateral Arteries Sep 11, 2023

Commentary by Dr. Valentin Fuster

Survival after Cardiac Transplantation in Adults with Single-Ventricle Congenital Heart Disease Sep 11, 2023

Commentary by Dr. Valentin Fuster

Comprehensive Management of ANOCA Part 1 – Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review Sep 11, 2023

Commentary by Dr. Valentin Fuster

Comprehensive Management of Anoca, Part 2—Program Development, Treatment, And Research Initiatives: Jacc State-Of-The-Art Review Sep 11, 2023

Commentary by Dr. Valentin Fuster

JACC - September 12, 2023 Issue Summary Sep 04, 2023

Audio Summary of the September 12 issue of JACC, by Dr. Valentin Fuster

Long-term Outcome and Prognosis of Non-Infectious Thoracic Aortitis Sep 04, 2023

Commentary by Dr. Valentin Fuster

Cardiovascular Events after Aortic Root Repair in Patients with Marfan Syndrome Sep 04, 2023

Commentary by Dr. Valentin Fuster

Underutilization of Mineralocorticoid Antagonists in Patients with Heart Failure and Reduced Ejection Fraction Sep 04, 2023

Commentary by Dr. Valentin Fuster

Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Hemodynamic Implications From Sinus Rate Analysis Sep 04, 2023

Commentary by Dr. Valentin Fuster

Ventricular Arrhythmias in Adults with Congenital Heart Disease Part I: JACC State-of-the-Art Review Sep 04, 2023

Commentary by Dr. Valentin Fuster

JACC - September 5, 2023 Issue Summary Aug 28, 2023

Audio Summary of the September 5 issue of JACC, by Dr. Valentin Fuster

Temporal trends in non-cardiovascular morbidity and mortality following acute myocardial infarction: A nationwide Danish study Aug 28, 2023

Commentary by Dr. Valentin Fuster

Long-term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction Aug 28, 2023

Commentary by Dr. Valentin Fuster

Trends in Mortality Following ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: 2003-2018 Aug 28, 2023

Commentary by Dr. Valentin Fuster

Efficacy of Dapagliflozin According To Geographical Location of Patients With Heart Failure Aug 28, 2023

Commentary by Dr. Valentin Fuster

Ablation To Reduce Atrial Fibrillation Burden And Improve Outcomes: Jacc Review Topic of the Week Aug 28, 2023

Commentary by Dr. Valentin Fuster

JACC - August 29, 2023 Issue Summary Aug 21, 2023

Audio Summary of the August 29 issue of JACC, by Dr. Valentin Fuster

Prevalence, Characteristics and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients Aug 21, 2023

Commentary by Dr. Valentin Fuster

Predictors of Mortality with a Fully Magnetically Levitated LVAD at 5-years: A MOMENTUM-3 Trial Analysis Aug 21, 2023

Commentary by Dr. Valentin Fuster

Age-Tailored Monitoring of Myocardial Involvement in Arrhythmogenic Cardiomyopathy Aug 21, 2023

Commentary by Dr. Valentin Fuster

Neighborhood Childhood Opportunity, Race/Ethnicity, and Surgical Outcomes in Children with Congenital Heart Disease Aug 21, 2023

Commentary by Dr. Valentin Fuster

JACC - August 22, 2023 Issue Summary Aug 14, 2023

Audio Summary of the August 22 issue of JACC, by Dr. Valentin Fuster

Return-to-Play for Elite Athletes with Genetic Heart Diseases Predisposing to Sudden Cardiac Death Aug 14, 2023

Commentary by Dr. Valentin Fuster

Cardiac Effects of Long Duration Space Flight Aug 14, 2023

Commentary by Dr. Valentin Fuster

Bleeding and Ischemic Risks of Ticagrelor Monotherapy after Coronary Interventions Aug 14, 2023

Commentary by Dr. Valentin Fuster

Right Atrial Adaptation to Precapillary Pulmonary Hypertension: Pressure-Volume, Cardiomyocyte and Histological Analysis Aug 14, 2023

Commentary by Dr. Valentin Fuster

Risk of Arrhythmic Death in Patients with Non-Ischemic Cardiomyopathy: JACC Review Topic of the Week Aug 14, 2023

Commentary by Dr. Valentin Fuster

ACC/AHA and ESC/EACTS Guidelines for the Management of Valvular Heart Diseases. JACC Guideline Comparison Aug 14, 2023

Commentary by Dr. Valentin Fuster

JACC - August 15, 2023 Issue Summary Aug 07, 2023

Audio Summary of the August 15 issue of JACC, by Dr. Valentin Fuster

First-in-Human Transapical Beating-Heart Septal Myectomy in Patients with Hypertrophic Obstructive Cardiomyopathy Aug 07, 2023

Commentary by Dr. Valentin Fuster

Subcutaneous Implantable Cardioverter Defibrillators in Patients with Congenital Heart Disease Aug 07, 2023

Commentary by Dr. Valentin Fuster

Fatal Cardiac Arrhythmias During Electronic Gaming In Patients With Genetically Mediated Heart Diseases Aug 07, 2023

Commentary by Dr. Valentin Fuster

Pulmonary Artery Hypoplasia in Neonates with Tetralogy of Fallot Aug 07, 2023

Commentary by Dr. Valentin Fuster

Low Dose Colchicine (0.5 mg daily) for the Secondary Prevention of Coronary Artery Disease Aug 07, 2023

Commentary by Dr. Valentin Fuster

Transformative Impact of Geroscience On Understanding Cvd In Older Adults And Developing New Therapeutic Strategies Aug 07, 2023

Commentary by Dr. Valentin Fuster

JACC - August 8, 2023 Issue Summary Jul 31, 2023

Audio Summary of the August 8 issue of JACC, by Dr. Valentin Fuster

High-Sensitivity Cardiac Troponin for Risk Assessment in Patients with Chronic Coronary Artery Disease Jul 31, 2023

Commentary by Dr. Valentin Fuster

Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction Jul 31, 2023

Commentary by Dr. Valentin Fuster

Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients with Ebstein Anomaly Jul 31, 2023

Commentary by Dr. Valentin Fuster

GLP1 Receptor Agonist Therapy with and without SGLT2 inhibitors in Patients with Type 2 Diabetes Jul 31, 2023

Commentary by Dr. Valentin Fuster

Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Review Topic of the Week Jul 31, 2023

Discover the 3 Focus Seminars commentated by Dr. Valentin Fuster, including "Implementing Guideline-Directed Medical Therapy" (0:50 | 10 min 4 sec) and "Bridging Treatment Implementation Gaps" (10:54 | 5 min 46 sec), along with essential guidelines for "Management of Worsening Heart Failure" (16:40 | 10 min 5 sec).

Management of Worsening Heart Failure With Reduced Ejection Fraction: Jacc Review Topic of the Week Jul 31, 2023

Discover the 3 Focus Seminars commentated by Dr. Valentin Fuster, including "Implementing Guideline-Directed Medical Therapy" (0:50 | 10 min 4 sec) and "Bridging Treatment Implementation Gaps" (10:54 | 5 min 46 sec), along with essential guidelines for "Management of Worsening Heart Failure" (16:40 | 10 min 5 sec).

Bridging Treatment Implementation Gaps In Patients With Heart Failure: Jacc Focus Seminar Jul 31, 2023

Discover the 3 Focus Seminars commentated by Dr. Valentin Fuster, including "Implementing Guideline-Directed Medical Therapy" (0:50 | 10 min 4 sec) and "Bridging Treatment Implementation Gaps" (10:54 | 5 min 46 sec), along with essential guidelines for "Management of Worsening Heart Failure" (16:40 | 10 min 5 sec).

JACC - August 1, 2023 Issue Summary Jul 24, 2023

Audio Summary of the August 1 issue of JACC, by Dr. Valentin Fuster

Post-approval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System Jul 24, 2023

Commentary by Dr. Valentin Fuster

Combination lipid-lowering therapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability Jul 24, 2023

Commentary by Dr. Valentin Fuster

C-Reactive Protein and Risk of Incident Heart Failure in Patients with Cardiovascular Disease Jul 24, 2023

Commentary by Dr. Valentin Fuster

Global Comparison of Re-admission Rates for Patients with Heart Failure Jul 24, 2023

Commentary by Dr. Valentin Fuster

Mechanisms of Aortic Dilation in Patients with Bicuspid Aortic Valve: JACC: State-of-the-Art Review Jul 24, 2023

Commentary by Dr. Valentin Fuster

JACC - July 25, 2023 Issue Summary Jul 17, 2023

Audio Summary of the July 25 issue of JACC, by Dr. Valentin Fuster

Short-term Outcomes of Tricuspid Edge-to-Edge Repair in Clinical Practice Jul 17, 2023

Commentary by Dr. Valentin Fuster

Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial Jul 17, 2023

Commentary by Dr. Valentin Fuster

Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State Jul 17, 2023

Commentary by Dr. Valentin Fuster

Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation Jul 17, 2023

Commentary by Dr. Valentin Fuster

JACC - July 18, 2023 Issue Summary Jul 10, 2023

Audio Summary of the July 18 issue of JACC, by Dr. Valentin Fuster

Five-Year Clinical Outcomes After Coronary Bioresorbable Scaffolds and Drug-Eluting Stents: The ABSORB IV Randomized Trial Jul 10, 2023

Commentary by Dr. Valentin Fuster

Dispatch of Volunteer Responders to Out-of-Hospital Cardiac Arrests Jul 10, 2023

Commentary by Dr. Valentin Fuster

Individualized Family Screening for Arrhythmogenic Right Ventricular Cardiomyopathy Jul 10, 2023

Commentary by Dr. Valentin Fuster

Comparison of Left Bundle-Branch Area Pacing to Biventricular Pacing in Candidates for Resynchronization Therapy Jul 10, 2023

Commentary by Dr. Valentin Fuster

Consumer Wearable Health and Fitness Technology in Cardiovascular Medicine: JACC State-of-the-Art Review Jul 10, 2023

Commentary by Dr. Valentin Fuster

JACC - July 11, 2023 Issue Summary Jul 03, 2023

Audio Summary of the July 11 issue of JACC, by Dr. Valentin Fuster

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events Jul 03, 2023

Commentary by Dr. Valentin Fuster

Outcomes of SAPIEN-3 Transcatheter Aortic Valve Replacement Compared with Surgical Valve Replacement in Intermediate-Risk Patients Jul 03, 2023

Commentary by Dr. Valentin Fuster

Impact of Malnutrition in Patients with Heart Failure and Secondary Mitral Regurgitation: COAPT Trial Jul 03, 2023

Commentary by Dr. Valentin Fuster

Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients with Heart Failure Jul 03, 2023

Commentary by Dr. Valentin Fuster

Cardiovascular Outcomes in Patients with Diabetes and Kidney Disease: JACC Review Topic of the Week Jul 03, 2023

Commentary by Dr. Valentin Fuster

Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week Jul 03, 2023

Commentary by Dr. Valentin Fuster

JACC - July 4, 2023 Issue Summary Jun 26, 2023

Audio Summary of the July 4 issue of JACC, by Dr. Valentin Fuster

Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure Jun 26, 2023

Commentary by Dr. Valentin Fuster

Long-term Outcomes of Women with Peripartum Cardiomyopathy having Subsequent Pregnancies Jun 26, 2023

Commentary by Dr. Valentin Fuster

Treatment of Idiopathic Recurrent Pericarditis with Goflikicept: Phase II/III Study Results Jun 26, 2023

Commentary by Dr. Valentin Fuster

Cognitive Behavioral Therapy Improves Quality of Life in Patients with Symptomatic Paroxysmal Atrial Fibrillation Jun 26, 2023

Commentary by Dr. Valentin Fuster

Single Troponin Measurement to Rule-out Myocardial Infarction: JACC Review Topic of the Week Jun 26, 2023

Commentary by Dr. Valentin Fuster

The Hemodynamic Effects of Continuous Lvad Support: Defining the Next Frontier To Improve Patient Longevity Jun 26, 2023

Commentary by Dr. Valentin Fuster

JACC - June 27, 2023 Issue Summary Jun 19, 2023

Audio Summary of the June 27 issue of JACC, by Dr. Valentin Fuster

Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations Jun 19, 2023

Commentary by Dr. Valentin Fuster

Assessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus Jun 19, 2023

Commentary by Dr. Valentin Fuster

Thrombus burden and outcome in patients with COVID-19 presenting with STEMI across the pandemic Jun 19, 2023

Commentary by Dr. Valentin Fuster

Mortality in patients with Ebstein anomaly: A population-based, two-country study of 530 patients Jun 19, 2023

Commentary by Dr. Valentin Fuster

Pulmonary Complications In Patients With Fontan Circulation Jun 19, 2023

Commentary by Dr. Valentin Fuster

Ventricular Arrhythmias Associated with Over-the-Counter and Recreational Opioids Jun 13, 2023

Commentary by Dr. Valentin Fuster

JACC - June 20, 2023 Issue Summary Jun 12, 2023

Audio Summary of the June 20 issue of JACC, by Dr. Valentin Fuster

Association of beta-blocker use with cardiovascular outcomes in patients with stable coronary artery disease Jun 12, 2023

Commentary by Dr. Valentin Fuster

Reduced Stress-Related Neural Network Activity Mediates the Effect of Alcohol on Cardiovascular Risk Jun 12, 2023

Commentary by Dr. Valentin Fuster

Incidence, Treatment and Outcomes of Symptomatic Lead-Related Venous Obstruction Among Medicare Patients in the US. Jun 12, 2023

Commentary by Dr. Valentin Fuster

Early Outcomes of Adult Heart Transplantations from COVID19 Donors in the U.S. Jun 12, 2023

Commentary by Dr. Valentin Fuster

Pulmonary vein stenosis: A review of pathogenesis, evaluation, and management Jun 12, 2023

Commentary by Dr. Valentin Fuster

JACC - June 13, 2023 Issue Summary Jun 12, 2023

Audio Summary of the June 13 issue of JACC, by Dr. Valentin Fuster

Spatial Transcriptional Mapping Reveals Site-Specific Pathways Underlying Human Atherosclerotic Plaque Rupture Jun 12, 2023

Commentary by Dr. Valentin Fuster

Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort Jun 12, 2023

Commentary by Dr. Valentin Fuster

Contribution of Migraine to Cardiovascular Disease Risk Prediction Jun 12, 2023

Commentary by Dr. Valentin Fuster

Remote Monitoring for Heart Failure Management at Home: JACC Scientific Statement Jun 12, 2023

Commentary by Dr. Valentin Fuster

JACC - June 6, 2023 Issue Summary May 29, 2023

Audio Summary of the June 6 issue of JACC, by Dr. Valentin Fuster

Intensive treatment up-titration after acute heart failure hospitalization across left ventricular ejection fraction spectrum May 29, 2023

Commentary by Dr. Valentin Fuster

Clinical Outcomes of Adult Fontan-Associated Liver Disease and Combined Heart-Liver Transplantation May 29, 2023

Commentary by Dr. Valentin Fuster

Morbidity and Mortality in Adult Fontan Patients after Heart or Combined Heart-Liver Transplantation May 29, 2023

Commentary by Dr. Valentin Fuster

Normative Echocardiographic Left Ventricular Parameters and Reference Intervals in Infants May 29, 2023

Commentary by Dr. Valentin Fuster

Contemporary multidisciplinary critical care management of electrical storm May 29, 2023

Commentary by Dr. Valentin Fuster

JACC - May 30, 2023 Issue Summary May 22, 2023

Audio Summary of the May 30 issue of JACC, by Dr. Valentin Fuster

Clinical screening for dilated cardiomyopathy in first-degree relatives: The DCM Precision Medicine Study May 22, 2023

Commentary by Dr. Valentin Fuster

Improved Survival after Pulmonary Valve Replacement in Repaired Tetralogy of Fallot May 22, 2023

Commentary by Dr. Valentin Fuster

Procedure-related complications of catheter ablation for atrial fibrillation: A systematic review and pooled analysis May 22, 2023

Commentary by Dr. Valentin Fuster

The Inflation Reduction Act and Out-of-Pocket Costs for Medicare Beneficiaries with Cardiovascular Disease May 22, 2023

Commentary by Dr. Valentin Fuster

Management of Mechanical Prosthetic Heart Valve Thrombosis: JACC Review Topic of the Week May 22, 2023

Commentary by Dr. Valentin Fuster

JACC - May 23, 2023 Issue Summary May 15, 2023

Audio Summary of the May 23 issue of JACC, by Dr. Valentin Fuster

Hemodynamic Assessment in Takotsubo Syndrome May 15, 2023

Commentary by Dr. Valentin Fuster

Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients with Atherosclerotic Cardiovascular Disease May 15, 2023

Commentary by Dr. Valentin Fuster

Natriuretic Response to Acetazolamide in Patients with Acute Heart Failure and Volume Overload May 15, 2023

Commentary by Dr. Valentin Fuster

Myocardial Injury Thresholds for Four High-sensitivity Troponin Assays in U.S. Adults May 15, 2023

Commentary by Dr. Valentin Fuster

Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week May 15, 2023

Commentary by Dr. Valentin Fuster

JACC - May 16, 2023 Issue Summary May 08, 2023

Audio Summary of the May 16 issue of JACC, by Dr. Valentin Fuster

Association of Cardiac Remodeling with Aortic Regurgitation Outcomes: The AR Consortium of the SCMR Registry May 08, 2023

Commentary by Dr. Valentin Fuster

Efficacy of Empagliflozin in Patients with Heart Failure Across Kidney Risk Categories May 08, 2023

Commentary by Dr. Valentin Fuster

Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients with ST-Segment Elevation Myocardial Infarction May 08, 2023

Commentary by Dr. Valentin Fuster

Patient-Reported Outcomes after Tetralogy of Fallot Repair May 08, 2023

Commentary by Dr. Valentin Fuster

Multimodality imaging of right heart function and impact on cardiovascular disease outcomes May 08, 2023

Commentary by Dr. Valentin Fuster

JACC - May 9, 2023 Issue Summary May 01, 2023

Audio Summary of the May 9 issue of JACC, by Dr. Valentin Fuster

Heart Failure with Preserved Ejection Fraction: JACC Scientific Statement May 01, 2023

Commentary by Dr. Valentin Fuster

Sex Difference in Outcomes of Acute Myocardial Infarction in Young Patients May 01, 2023

Commentary by Dr. Valentin Fuster

Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes May 01, 2023

Commentary by Dr. Valentin Fuster

One-Year Outcomes of Transcatheter Tricuspid Valve Repair May 01, 2023

Commentary by Dr. Valentin Fuster

Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial May 01, 2023

Commentary by Dr. Valentin Fuster

JACC - May 2, 2023 Issue Summary Apr 24, 2023

Audio Summary of the May 2 issue of JACC, by Dr. Valentin Fuster

Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis Apr 24, 2023

Commentary by Dr. Valentin Fuster

Virtual Care Team-Guided Therapeutic Optimization During Hospitalization in Patients with Heart Failure: The IMPLEMENT-HF Study Apr 24, 2023

Commentary by Dr. Valentin Fuster

Health Status and Clinical Outcomes in Older Adults with Chronic Coronary Disease: ISCHEMIA Trial Apr 24, 2023

Commentary by Dr. Valentin Fuster

Low Utilization of Lead Extraction Among Patients with Cardiac Implantable Electronic Devices and Infective Endocarditis Apr 24, 2023

Commentary by Dr. Valentin Fuster

Gut Microbiome-based Approach to Management of Patients with Heart Failure Apr 24, 2023

Commentary by Dr. Valentin Fuster

JACC - April 25, 2023 Issue Summary Apr 17, 2023

Audio Summary of the March 28 issue of JACC, by Dr. Valentin Fuster

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial Apr 17, 2023

Commentary by Dr. Valentin Fuster

The clinical and prognostic relevance of cardiac wasting in patients with advanced cancer:A prospective study. Apr 17, 2023

Commentary by Dr. Valentin Fuster

Exercise Capacity, NT-pro BNP and Exercise Hemodynamics in Adults Post-Fontan Apr 17, 2023

Commentary by Dr. Valentin Fuster

Long-Term Healthcare Utilization after Cardiac Surgery in Children Covered under Medicaid Apr 17, 2023

Commentary by Dr. Valentin Fuster

Familial Hypercholesterolemia: Challenges for a High-Risk Population Apr 17, 2023

Commentary by Dr. Valentin Fuster

Triglyceride Rich Lipoprotein Lowering Therapies: Considerations for Clinical Trial Design Targeting Atherosclerotic Cardiovascular Disease Apr 17, 2023

Commentary by Dr. Valentin Fuster

Lipoprotein(a) Lowering Therapies: Considerations for Clinical Trial Design for Atherosclerotic Cardiovascular Disease Risk Reduction Apr 17, 2023

Commentary by Dr. Valentin Fuster

JACC - April 18, 2023 Issue Summary Apr 10, 2023

Audio Summary of the March 28 issue of JACC, by Dr. Valentin Fuster

Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure Apr 10, 2023

Commentary by Dr. Valentin Fuster

Heart Failure Following Anti-inflammatory Medications in Patients with Type 2 Diabetes Mellitus Apr 10, 2023

Commentary by Dr. Valentin Fuster

Impact of Age and Sex on Left Ventricular Remodeling and Outcomes in Chronic Aortic Regurgitation Apr 10, 2023

Commentary by Dr. Valentin Fuster

Out-of-Pocket Drug Costs for Medicare Beneficiaries with Cardiovascular Risk Factors/Conditions Under the Inflation Reduction Act Apr 10, 2023

Commentary by Dr. Valentin Fuster

Evolving Science on Cardiovascular Disease among Hispanic/Latino Adults: JACC International Apr 10, 2023

Commentary by Dr. Valentin Fuster

JACC - April 11, 2023 Issue Summary Apr 03, 2023

Audio Summary of the March 28 issue of JACC, by Dr. Valentin Fuster

Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care Apr 03, 2023

Commentary by Dr. Valentin Fuster

The Genetic Determinants of Aortic Distension Apr 03, 2023

Commentary by Dr. Valentin Fuster

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients with Atherosclerosis Apr 03, 2023

Commentary by Dr. Valentin Fuster

Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users Apr 03, 2023

Commentary by Dr. Valentin Fuster

Assessing and Addressing Social Determinants of Health in Cardiovascular Care - Clinic and Health Systems Approaches Apr 03, 2023

Commentary by Dr. Valentin Fuster

JACC - April 4, 2023 Issue Summary Mar 28, 2023

Audio Summary of the March 28 issue of JACC, by Dr. Valentin Fuster

Identification of High-Risk Coronary Lesions by Three-Vessel Optical Coherence Tomography Mar 28, 2023

Commentary by Dr. Valentin Fuster

Impact of Moderate Aortic Stenosis in Patients with Heart Failure with Reduced Ejection Fraction Mar 28, 2023

Commentary by Dr. Valentin Fuster

Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis Mar 28, 2023

Commentary by Dr. Valentin Fuster

Hematopoietic Somatic Mosaicism is Associated with an Increased Risk of Postoperative Atrial Fibrillation Mar 28, 2023

Commentary by Dr. Valentin Fuster

Early Lead Extraction for Infected Implanted Cardiac Electronic Devices: JACC Review Topic of the Week Mar 28, 2023

Commentary by Dr. Valentin Fuster

JACC - March 28, 2023 Issue Summary Mar 20, 2023

Audio Summary of the March 28 issue of JACC, by Dr. Valentin Fuster

Changes in Cardiorespiratory Fitness and Survival in Patients with or without Cardiovascular Disease Mar 20, 2023

Commentary by Dr. Valentin Fuster

Association of Incident Cardiovascular Disease with Time Course and Cumulative Exposure to Multiple Risk Factors Mar 20, 2023

Commentary by Dr. Valentin Fuster

Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock with Cardiac Arrest Mar 20, 2023

Commentary by Dr. Valentin Fuster

Representation of Women and Minority Faculty and Fellows in Academic Pediatric Cardiology Training Programs Mar 20, 2023

Commentary by Dr. Valentin Fuster

Abnormal Conduction-Induced Cardiomyopathy: JACC Review Topic of the Week Mar 20, 2023

Commentary by Dr. Valentin Fuster

JACC - March 21, 2023 Issue Summary Mar 13, 2023

Audio Summary of the March 21 issue of JACC, by Dr. Valentin Fuster

Sudden Cardiac Death among Adolescents in the United Kingdom Mar 13, 2023

Commentary by Dr. Valentin Fuster

Incidence of Cardiac Arrest during Sports among Women in the European Union Mar 13, 2023

Commentary by Dr. Valentin Fuster

Risk of Sudden Death in Patients with RASopathy Hypertrophic Cardiomyopathy Mar 13, 2023

Commentary by Dr. Valentin Fuster

Geographic Variation in Cardiac Rehabilitation Access Mar 13, 2023

Commentary by Dr. Valentin Fuster

2023 Acc Expert Consensus Decision Pathway On Comprehensive Multidisciplinary Care For the Patient With Cardiac Amyloidosis Mar 13, 2023

Commentary by Dr. Valentin Fuster

JACC - March 14, 2023 Issue Summary Mar 06, 2023

Audio Summary of the March 14 issue of JACC, by Dr. Valentin Fuster

Sex differences in epidemiology, care processes and clinical outcomes for acute chest pain Mar 06, 2023

Commentary by Dr. Valentin Fuster

Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring Mar 06, 2023

Commentary by Dr. Valentin Fuster

Effect of Prosthesis-Patient Mismatch on Long-term Clinical Outcomes after Bioprosthetic Aortic Valve Replacement Mar 06, 2023

Commentary by Dr. Valentin Fuster

Prevalence and Complications of Aberrant Subclavian Artery in Patients with Heritable and Non-Heritable Arteriopathies Mar 06, 2023

Commentary by Dr. Valentin Fuster

JACC - March 7, 2023 Issue Summary Feb 27, 2023

Audio Summary of the March 7 issue of JACC, by Dr. Valentin Fuster

Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients with Heart Failure Feb 27, 2023

Commentary by Dr. Valentin Fuster

Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures Feb 27, 2023

Commentary by Dr. Valentin Fuster

Prevalence and Clinical Implications of Tricuspid Valve Prolapse Based on Magnetic Resonance Diagnostic Criteria Feb 27, 2023

Commentary by Dr. Valentin Fuster

Association between Shock Etiology and 5-Year Outcomes after Veno-Arterial Extracorporeal Membrane Oxygenation Feb 27, 2023

Commentary by Dr. Valentin Fuster

Clinical Applications and Potential Pitfalls of Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk Feb 27, 2023

Commentary by Dr. Valentin Fuster

JACC - February 28, 2023 Issue Summary Feb 20, 2023

Audio Summary of the February 28 issue of JACC, by Dr. Valentin Fuster

Vein Graft Use and Long-term Survival Following Coronary Bypass Grafting Feb 20, 2023

Commentary by Dr. Valentin Fuster

Outcomes of Simultaneous Heart And Kidney Transplantation Feb 20, 2023

Commentary by Dr. Valentin Fuster

Cardiac Damage and Quality of Life after Aortic Valve Replacement in the PARTNER Trials Feb 20, 2023

Commentary by Dr. Valentin Fuster

Short-Term Risk Stratification of Non-Flow Limiting Coronary Stenosis by Angiographically Derived Radial Wall Strain Feb 20, 2023

Commentary by Dr. Valentin Fuster

Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week Feb 20, 2023

Commentary by Dr. Valentin Fuster

Editor-In-Chief'S Top Picks From 2022 Feb 20, 2023

Commentary by Dr. Valentin Fuster

2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology (Coronary, Peripheral Vascular, and Structural Heart Interventions): A Report of the ACC Competency Management Committee Feb 16, 2023

Dr. Ehtisham Mahmud, on behalf of the document leadership team and writing committee for the ACC/AHA/SCAI Interventional Cardiology Advanced Training Statement, presents a high-level overview of the cardiovascular profession’s first document covering the breadth of interventional cardiology training, including coronary, peripheral vascular, structural heart, and adult congenital heart interventions.

JACC - February 21, 2023 Issue Summary Feb 13, 2023

Commentary by Dr. Valentin Fuster

Incidence of Atherosclerotic Cardiovascular Disease In Young Adults At Low Short-Term But High Long-Term Risk Feb 13, 2023

Commentary by Dr. Valentin Fuster

Risk of Surgical Mitral Valve Repair For Primary Mitral Regurgitation Feb 13, 2023

Commentary by Dr. Valentin Fuster

Left Ventricular Filling Pressure In Chronic Thromboembolic Pulmonary Hypertension Feb 13, 2023

Commentary by Dr. Valentin Fuster

Association Between Number of Volunteer Responders Arriving Before the Ambulance And Bystander Interventions Feb 13, 2023

Commentary by Dr. Valentin Fuster

Bleeding Events After Transcatheter Aortic Valve Replacement: Jacc State-Of-The-Art Review Feb 13, 2023

Commentary by Dr. Valentin Fuster

JACC - February 14, 2023 Issue Summary Feb 06, 2023

Audio Summary of the February 14 issue of JACC, by Dr. Valentin Fuster

Impact of Transcatheter Mitral Valve Repair Availability on Volume and Outcomes of Surgical Repair Feb 06, 2023

Commentary by Dr. Valentin Fuster

P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy after Complex Percutaneous Coronary Interventions Feb 06, 2023

Commentary by Dr. Valentin Fuster

Acute Cardiac Events during COVID-19-Associated Hospitalizations Feb 06, 2023

Commentary by Dr. Valentin Fuster

Prevalence and Professional Impact of Mental Health Conditions among Cardiologists Feb 06, 2023

Commentary by Dr. Valentin Fuster

Combined Minimally Invasive Surgical and Percutaneous Catheter Ablation of Atrial Fibrillation Feb 06, 2023

Commentary by Dr. Valentin Fuster

JACC - February 7, 2023 Issue Summary Jan 30, 2023

Audio Summary of the February 7 issue of JACC, by Dr. Valentin Fuster

Transcatheter Edge-to-Edge Repair in Patients with Anatomically Complex Degenerative Mitral Regurgitation Jan 30, 2023

Commentary by Dr. Valentin Fuster

Acute Coronary Occlusion in Patients with Non-ST-segment Elevation Out-of-hospital Cardiac Arrest Jan 30, 2023

Commentary by Dr. Valentin Fuster

Effect of Dapagliflozin on Health Status in Patients with Preserved or Mildly Reduced Ejection Fraction Jan 30, 2023

Commentary by Dr. Valentin Fuster

Phenotypes of Overdiagnosed Long QT Syndrome Jan 30, 2023

Commentary by Dr. Valentin Fuster

Challenges in Cardiovascular Evaluation and Management of Obese Patients: JACC State-of-the-Art Review Jan 30, 2023

Commentary by Dr. Valentin Fuster

JACC - January 24, 2023 Issue Summary Jan 16, 2023

Audio Summary of the January 24 issue of JACC, by Dr. Valentin Fuster

Implementation of High-Sensitivity Cardiac Troponin Assays in the United States Jan 16, 2023

Commentary by Dr. Valentin Fuster

PCSK9 Inhibition during the Inflammatory Stage of SARS-CoV-2 Infection Jan 16, 2023

Commentary by Dr. Valentin Fuster

Comparison of Drug-coated Balloons versus Bare Metal Stents in Patients with Femoropopliteal Arterial Disease Jan 16, 2023

Commentary by Dr. Valentin Fuster

Declining Incidence of Postoperative Neonatal Brain Injury in Congenital Heart Disease Jan 16, 2023

Commentary by Dr. Valentin Fuster

Albuminuria and Heart Failure: JACC State of the Art Review Jan 16, 2023

Commentary by Dr. Valentin Fuster

JACC - January 17, 2023 Issue Summary Jan 09, 2023

Audio Summary of the January 17 issue of JACC, by Dr. Valentin Fuster

Survival after Septal Reduction in Patients >65 years old with Obstructive Hypertrophic Cardiomyopathy Jan 09, 2023

Commentary by Dr. Valentin Fuster

Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections Jan 09, 2023

Commentary by Dr. Valentin Fuster

Elevated LDL-Triglycerides and Atherosclerotic Risk Jan 09, 2023

Commentary by Dr. Valentin Fuster

Improving Risk Stratification for Patients with Type 2 Myocardial Infarction Jan 09, 2023

Commentary by Dr. Valentin Fuster

JACC Focus Seminar Tropical Medicine: Cardiomyopathies and Nutritional Heart Disease Jan 09, 2023

Commentary by Dr. Valentin Fuster

JACC Focus Seminar Tropical Medicine: Cardiomyopathies and Nutritional Heart Disease Jan 09, 2023

Commentary by Dr. Valentin Fuster

Takayasu Arteritis: JACC Focus Seminar Jan 09, 2023

Commentary by Dr. Valentin Fuster

JACC - January 3-10, 2023 Issue Summary Jan 02, 2023

Audio Summary of the January 3-10 issue of JACC, by Dr. Valentin Fuster

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers Jan 02, 2023

Commentary by Dr. Valentin Fuster

Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials Jan 02, 2023

Commentary by Dr. Valentin Fuster

Phase 2 Study of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Jan 02, 2023

Commentary by Dr. Valentin Fuster

Outcomes of Percutaneous Intervention in Patients with Takayasu Arteritis Jan 02, 2023

Commentary by Dr. Valentin Fuster

Jacc Focus Seminar Series- 'Tropical Medicine' Jan 02, 2023

Commentary by Dr. Valentin Fuster

JACC - December 20, 2022 Issue Summary Dec 12, 2022

Audio Summary of the December 20 issue of JACC, by Dr. Valentin Fuster

JACC - December 13, 2022 Issue Summary Dec 05, 2022

Audio Summary of the December 13 issue of JACC, by Dr. Valentin Fuster

Prognosis of Myocarditis Developing after mRNA COVID-19 Vaccination Compared With Viral Myocarditis Dec 05, 2022

Commentary by Dr. Valentin Fuster

Micronutrient Supplementation to Reduce Cardiovascular Risk Dec 05, 2022

Commentary by Dr. Valentin Fuster

Incidence and Burden of Tricuspid Regurgitation in Patients with Atrial Fibrillation Dec 05, 2022

Commentary by Dr. Valentin Fuster

Edoxaban for Thromboembolism Prevention in Pediatric Patients with Cardiac Disease Dec 05, 2022

Commentary by Dr. Valentin Fuster

JACC - December 6, 2022 Issue Summary Nov 28, 2022

Audio Summary of the December 6 issue of JACC, by Dr. Valentin Fuster

Adding Salt to Foods and Risk of Cardiovascular Disease Nov 28, 2022

Commentary by Dr. Valentin Fuster

2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients with Annular Calcification, Rings and Bioprostheses Nov 28, 2022

Commentary by Dr. Valentin Fuster

Ultrasonic Texture Features for Assessing Cardiac Remodeling and Dysfunction Nov 28, 2022

Commentary by Dr. Valentin Fuster

Enhanced Mitochondrial Calcium Uptake Suppresses Atrial Fibrillation Associated with Metabolic Syndrome Nov 28, 2022

Commentary by Dr. Valentin Fuster

Management of Heart Failure with Arrhythmia in Adults with Congenital Heart Disease: JACC State-of-the-Art Review Nov 28, 2022

Commentary by Dr. Valentin Fuster

JACC - November 29, 2022 Issue Summary Nov 21, 2022

Audio Summary of the November 29 issue of JACC, by Dr. Valentin Fuster

Concealed Cardiomyopathy in Autopsy-Inconclusive Cases of Sudden Cardiac Death and Implications for Families Nov 21, 2022

Commentary by Dr. Valentin Fuster

Transcatheter Edge-to-Edge Repair in Patients with Severe Mitral Regurgitation and Cardiogenic Shock: TVT Registry Analysis Nov 21, 2022

Commentary by Dr. Valentin Fuster

Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial Nov 21, 2022

Commentary by Dr. Valentin Fuster

Race-dependent association of high-density lipoprotein cholesterol levels with incident coronary heart disease in REGARDS Nov 21, 2022

Commentary by Dr. Valentin Fuster

A Practical Approach to Left Main Coronary Artery Disease: JACC State-of-the-Art Review Nov 21, 2022

Commentary by Dr. Valentin Fuster

JACC - November 22, 2022 Issue Summary Nov 14, 2022

Audio Summary of the November 22 issue of JACC, by Dr. Valentin Fuster

Coronary Calcium Scoring Improves Risk Prediction in Patients With Suspected Obstructive Coronary Artery Disease Nov 14, 2022

Commentary by Dr. Valentin Fuster

Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies Nov 14, 2022

Commentary by Dr. Valentin Fuster

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease Nov 14, 2022

Commentary by Dr. Valentin Fuster

Outcomes of Pregnancy in Women With Bioprosthetic Heart Valves With or Without Valve Dysfunction Nov 14, 2022

Commentary by Dr. Valentin Fuster

Randomized Trials of Percutaneous Microaxial Flow Pump Devices Nov 14, 2022

Commentary by Dr. Valentin Fuster

2022 ACC Health Policy Statement on Career Flexibility in Cardiology Nov 09, 2022

Drs. Mary Norine Walsh and Sharonne N. Hayes discuss the 2022 ACC Health Policy Statement on career flexibility in cardiology

JACC - November 15, 2022 Issue Summary Nov 07, 2022

Audio Summary of the November 15 issue of JACC, by Dr. Valentin Fuster

Hospitalizations and Mortality in Patients with Secondary Mitral Regurgitation and Heart Failure: COAPT Trial Nov 07, 2022

Commentary by Dr. Valentin Fuster

Cardiovascular Risk Reduction after Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range Nov 07, 2022

Commentary by Dr. Valentin Fuster

Neurometabolism and Ventricular Dyssynchrony in Patients with Heart Failure and Reduced Ejection Fraction Nov 07, 2022

Commentary by Dr. Valentin Fuster

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines Nov 07, 2022

Commentary by Dr. Valentin Fuster

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir in Patients with COVID-19: JACC Review Topic of the Week Nov 07, 2022

Commentary by Dr. Valentin Fuster

Coronary Artery Bypass Surgery without Saphenous Vein Grafting: JACC: Review Topic of the Week Nov 01, 2022

Commentary by Dr. Valentin Fuster

JACC - November 8, 2022 Issue Summary Nov 01, 2022

Audio Summary of the November 8 issue of JACC, by Dr. Valentin Fuster

Benefit of Dapagliflozin in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction Oct 31, 2022

Commentary by Dr. Valentin Fuster

Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction Oct 31, 2022

Commentary by Dr. Valentin Fuster

Air Pollution and Coronary Vasomotor Disorders in Patients with Myocardial Ischemia and Non-Obstructive Coronary Arteries. Oct 31, 2022

Commentary by Dr. Valentin Fuster

In-Hospital Cardiac Arrest Complicating ST-Segment Elevation Myocardial Infarction: Findings from CCC-ACS Project Oct 31, 2022

Commentary by Dr. Valentin Fuster

JACC - October 25, 2022 Issue Summary Oct 17, 2022

Audio Summary of the October 25 issue of JACC, by Dr. Valentin Fuster

Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes Oct 17, 2022

Commentary by Dr. Valentin Fuster

Impact of Periprocedural Pulmonary Hypertension on Outcomes after Transcatheter Aortic Valve Replacement Oct 17, 2022

Commentary by Dr. Valentin Fuster

Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy is Prognostic for Post-Transplant Events Oct 17, 2022

Commentary by Dr. Valentin Fuster

Circulating T-Cells and Cardiovascular Risk in People with and without Human Immunodeficiency Virus Infection Oct 17, 2022

Commentary by Dr. Valentin Fuster

Diaphragmatic Function in Cardiovascular Disease: JACC: Review Topic of the Week Oct 17, 2022

Commentary by Dr. Valentin Fuster

JACC - October 18, 2022 Issue Summary Oct 10, 2022

Audio Summary of the October 18 issue of JACC, by Dr. Valentin Fuster

Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery Oct 10, 2022

Commentary by Dr. Valentin Fuster

Intensive Blood Pressure Lowering in Patients with Malignant Left Ventricular Hypertrophy Oct 10, 2022

Commentary by Dr. Valentin Fuster

Dose-Response to Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Oct 10, 2022

Commentary by Dr. Valentin Fuster

Impact of Clonal Hematopoiesis in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Oct 10, 2022

Commentary by Dr. Valentin Fuster

Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review Oct 10, 2022

Commentary by Dr. Valentin Fuster

JACC - October 11, 2022 Issue Summary Oct 03, 2022

Audio Summary of the October 11 issue of JACC, by Dr. Valentin Fuster

Cardiac Outcomes in Adults with Mitochondrial Disease Oct 03, 2022

Commentary by Dr. Valentin Fuster

Impediments to Heart Transplantation in Adults with MelasMT-TL1:m.3243A>G Cardiomyopathy Oct 03, 2022

Commentary by Dr. Valentin Fuster

Natural History of MYH7-related Dilated Cardiomyopathy Oct 03, 2022

Commentary by Dr. Valentin Fuster

Peripartum Screening for Postpartum Hypertension in Women with Hypertensive Disorders of Pregnancy Oct 03, 2022

Commentary by Dr. Valentin Fuster

Cardiac Phenotypes in Secondary Hypertension: JACC State-of-the-Art Review Oct 03, 2022

Commentary by Dr. Valentin Fuster

JACC - October 4, 2022 Issue Summary Sep 26, 2022

Audio Summary of the October 4 issue of JACC, by Dr. Valentin Fuster

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes Sep 26, 2022

Commentary by Dr. Valentin Fuster

Dapagliflozin in Patients Recently Hospitalized with Heart Failure and Mildly Reduced and Preserved Ejection Fraction Sep 26, 2022

Commentary by Dr. Valentin Fuster

Hemodynamic and Clinical Performance of Hearts Donated After Circulatory Death Sep 26, 2022

Commentary by Dr. Valentin Fuster

Population-based Recalibration of the Framingham Risk Score and Pooled Cohort Equations Sep 26, 2022

Commentary by Dr. Valentin Fuster

The Athlete’s Heart – Challenges and Controversies: JACC Focus Seminar Sep 26, 2022

Commentary by Dr. Valentin Fuster

2022 Acc Expert Consensus Decision Pathway On the Role of Nonstatin Therapies For Ldl-Cholesterol Lowering In the Management of Atherosclerotic Cardiovascular Disease Risk Sep 26, 2022

Commentary by Dr. Valentin Fuster

JACC - September 27, 2022 Issue Summary Sep 19, 2022

Audio Summary of the September 27 issue of JACC, by Dr. Valentin Fuster

Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy Sep 19, 2022

Commentary by Dr. Valentin Fuster

Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk Sep 19, 2022

Commentary by Dr. Valentin Fuster

Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention Sep 19, 2022

Commentary by Dr. Valentin Fuster

Coronary Intervention Guided by Quantitative Flow Ratio vs. Angiography in Patients with or without Diabetes Sep 19, 2022

Commentary by Dr. Valentin Fuster

Athletic Activity for Patients with Hypertrophic Cardiomyopathy and Other Inherited Cardiovascular Diseases: JACC Focus Seminar Sep 19, 2022

Commentary by Dr. Valentin Fuster

JACC - September 20, 2022 Issue Summary Sep 12, 2022

Audio Summary of the September 20 issue of JACC, by Dr. Valentin Fuster

Clinical Risk Score to Predict Pathogenic Genotypes in Patients with Dilated Cardiomyopathy Sep 12, 2022

Commentary by Dr. Valentin Fuster

Sacubitril/Valsartan and Frailty in Patients with Heart Failure and Preserved Ejection Fraction Sep 12, 2022

Commentary by Dr. Valentin Fuster

Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients with Diabetes Sep 12, 2022

Commentary by Dr. Valentin Fuster

Clinical Predictors of Recurrent Supraventricular Tachycardia in Infancy Sep 12, 2022

Commentary by Dr. Valentin Fuster

Heart Failure with Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar Sep 12, 2022

Commentary by Dr. Valentin Fuster

JACC - September 13, 2022 Issue Summary Sep 05, 2022

Audio Summary of the September 13 issue of JACC, by Dr. Valentin Fuster

Infective Endocarditis, Invasive-Dental Procedures and Antibiotic Prophylaxis: Case-Crossover and Cohort Studies in a US Population Sep 05, 2022

Commentary by Dr. Valentin Fuster

Clinical Outcomes in Patients with Dilated Cardiomyopathy and Ventricular Tachycardia Sep 05, 2022

Commentary by Dr. Valentin Fuster

Outcomes of Repair of Congenital Aortic Valve Lesions using Autologous Pericardium vs Porcine Intestinal Submucosa Sep 05, 2022

Commentary by Dr. Valentin Fuster

Impact of Left Ventricular Ejection Fraction on Clinical Outcomes in Bicuspid Aortic Valve Disease Sep 05, 2022

Commentary by Dr. Valentin Fuster

Exercise, Cardiovascular Disease, and the Athlete’s Heart Sep 05, 2022

Commentary by Dr. Valentin Fuster

Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4 Sep 05, 2022

Commentary by Dr. Valentin Fuster

JACC - September 6, 2022 Issue Summary Aug 29, 2022

Audio Summary of the September 6 issue of JACC, by Dr. Valentin Fuster

Long-Term Outcomes after Atrial Switch Operation for Transposition of the Great Arteries Aug 29, 2022

Commentary by Dr. Valentin Fuster

Screening for cardiac amyloidosis 5-15 years after surgery for bilateral carpal tunnel syndrome (CACTUS study) Aug 29, 2022

Commentary by Dr. Valentin Fuster

Validated Model for Prediction of Adverse Cardiac Outcome in Patients with Fabry Disease Aug 29, 2022

Commentary by Dr. Valentin Fuster

Cathepsin-S Levels and Survival among Patients with Non-ST Elevation Acute Coronary Syndromes Aug 29, 2022

Commentary by Dr. Valentin Fuster

Ischemic Heart Disease in Young Women: JACC Review Topic of the Week Aug 29, 2022

Commentary by Dr. Valentin Fuster

JACC - August 30, 2022 Issue Summary Aug 22, 2022

Audio Summary of the August 30 issue of JACC, by Dr. Valentin Fuster

Comparative Risks of Initial Aortic Events Associated with Genetic Thoracic Aortic Disease Aug 22, 2022

Commentary by Dr. Valentin Fuster

Polygenic Risk Score Predicts Sudden Death in Patients with Coronary Disease and Preserved Systolic Function Aug 22, 2022

Commentary by Dr. Valentin Fuster

Biomarker prediction of major coronary events and complex revascularization procedures in the FOURIER trial Aug 22, 2022

Commentary by Dr. Valentin Fuster

Impact and Modifiers of Ventricular Pacing in Patients with Single Ventricle Circulation Aug 22, 2022

Commentary by Dr. Valentin Fuster

Severe Mental Illness and Cardiovascular Disease: JACC State-of-the-Art Review Aug 22, 2022

Commentary by Dr. Valentin Fuster

Lipoprotein(a), Ancestry and Cardiovascular Risk Thresholds Aug 22, 2022

Commentary by Dr. Valentin Fuster

JACC - August 23, 2022 Issue Summary Aug 15, 2022

Audio Summary of the August 23 issue of JACC, by Dr. Valentin Fuster

Association of Medication Adherence with Health Outcomes in the ISCHEMIA Trial Aug 15, 2022

Commentary by Dr. Valentin Fuster

Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy Aug 15, 2022

Commentary by Dr. Valentin Fuster

Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement Aug 15, 2022

Commentary by Dr. Valentin Fuster

The Association of Socioeconomic Status With Hypertension in 76 Low- and Middle-Income Countries Aug 15, 2022

Commentary by Dr. Valentin Fuster

Repair of Abdominal Aortic Aneurysms: JACC Focus Seminar Aug 15, 2022

Commentary by Dr. Valentin Fuster

Inflammatory Diseases of the Aorta: JACC Focus Seminar Aug 15, 2022

Commentary by Dr. Valentin Fuster

Thoracoabdominal Aortic Disease and Repair: JACC Focus Seminar Aug 15, 2022

Commentary by Dr. Valentin Fuster

JACC - August 9, 2022 Issue Summary Aug 01, 2022

Audio Summary of the August 9 issue of JACC, by Dr. Valentin Fuster

Cardiovascular Disease Projections In the United States Based On the 2020 Census Aug 01, 2022

Commentary by Dr. Valentin Fuster

Sustained-Release Ivabradine Hemisulfate In Patients With Systolic Heart Failure Aug 01, 2022

Commentary by Dr. Valentin Fuster

Cardiorespiratory Fitness And Mortality Risk Across the Spectrum of Age, Race, And Gender Aug 01, 2022

Commentary by Dr. Valentin Fuster

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected